ID,Year,acute.sustained_animal,sample.group.size_intervention_animal,outcome.count_intervention_animal,outcome.direction_animal,gnotobiotic,animal.strain,animal.sex,species,disease.model,success.measure,p.t.intervention_animal,ribotype,c.diff.strain,intervention_animal,animal.age.value..days.,animal.weight.value..g.,c.diff.dose.value,c.diff.dose.units,c.diff.dose.vegetative.spores,daily.dosage_intervention_animal,total.dosage_intervention_animal,comparator_animal,p.t.comparator_animal,sample.group.size_comparator_animal,outcome.count_comparator_animal,daily.dosage_comparator_animal,total.dosage_comparator_animal,s.p.value_animal,i.p.value_animal,case.ID,acute.sustained_human,daily.dosage.intervention_human,total.dosage.intervention_human,dosage.value,dosage.units,dosage.times.per.day,dosage.duration,dosage.comment,intervention.class,intervention_human,dose.dependence,sample.group.size_intervention_human,p.t.human,outcome,outcome.direction_human,measure.description,outcome.group.size,author.conclusion,conclusion.method,References,NCT.Number,Title,Gender,Age.Groups,Age.Description,Phases,URL,outcome.count_intervention_human,comparator.class,comparator_human,sample.group.size_comparator_human,outcome.count_comparator_human,daily.dosage.comparator_human,total.dosage.comparator_human,s.p.value_human,i.p.value_human,intervention-match-type,comparator-match-type,preclinical_conclusion,clinical_conclusion,exact_translation
25486992,2015,sustained,5,4,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,5.0,25.0,control,therapeutic,15,8,,,0.206531685156,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,vancomycin,378,281,,,0.000333838594497,1.0,intervention.Variation,comparator.Variation,inconclusive,superior,0
25486992,2015,sustained,5,4,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,5.0,25.0,control,therapeutic,15,8,,,0.206531685156,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,vancomycin + metronidazole,378,281,,,0.000333838594497,1.0,intervention.Variation,comparator.Variation,inconclusive,superior,0
25486992,2015,sustained,5,4,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,5.0,25.0,control,therapeutic,15,8,,,0.206531685156,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,metronidazole,378,281,,,0.000333838594497,1.0,intervention.Variation,comparator.Variation,inconclusive,superior,0
25486992,2015,sustained,5,4,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,5.0,25.0,control,therapeutic,15,8,,,0.206531685156,1.0,NCT00350298-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,101,therapeutic,Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) [ Time Frame: Day 0 to Day 84 ],positive,participants,7,,,x,NCT00350298,Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00350298,7,control,normal saline,99,74,,,1.0,8.109741066219999e-25,intervention.Specific,control,inconclusive,inferior,0
25486992,2015,sustained,5,4,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,5.0,25.0,control,therapeutic,15,8,,,0.206531685156,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,Placebo + Standard of Care,378,281,,,0.000333838594497,1.0,intervention.Variation,control,inconclusive,superior,0
25486992,2015,sustained,5,4,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,5.0,25.0,control,therapeutic,10,1,,,0.0090957804691,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,vancomycin,378,281,,,0.000333838594497,1.0,intervention.Variation,comparator.Variation,superior,superior,1
25486992,2015,sustained,5,4,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,5.0,25.0,control,therapeutic,10,1,,,0.0090957804691,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,vancomycin + metronidazole,378,281,,,0.000333838594497,1.0,intervention.Variation,comparator.Variation,superior,superior,1
25486992,2015,sustained,5,4,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,5.0,25.0,control,therapeutic,10,1,,,0.0090957804691,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,metronidazole,378,281,,,0.000333838594497,1.0,intervention.Variation,comparator.Variation,superior,superior,1
25486992,2015,sustained,5,4,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,5.0,25.0,control,therapeutic,10,1,,,0.0090957804691,1.0,NCT00350298-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,101,therapeutic,Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) [ Time Frame: Day 0 to Day 84 ],positive,participants,7,,,x,NCT00350298,Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00350298,7,control,normal saline,99,74,,,1.0,8.109741066219999e-25,intervention.Specific,control,superior,inferior,0
25486992,2015,sustained,5,4,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,5.0,25.0,control,therapeutic,10,1,,,0.0090957804691,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,Placebo + Standard of Care,378,281,,,0.000333838594497,1.0,intervention.Variation,control,superior,superior,1
25486992,2015,sustained,5,5,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,50.0,50.0,control,therapeutic,15,8,,,0.03550282872,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,vancomycin,378,281,,,0.000333838594497,1.0,intervention.Variation,comparator.Variation,superior,superior,1
25486992,2015,sustained,5,5,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,50.0,50.0,control,therapeutic,15,8,,,0.03550282872,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,vancomycin + metronidazole,378,281,,,0.000333838594497,1.0,intervention.Variation,comparator.Variation,superior,superior,1
25486992,2015,sustained,5,5,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,50.0,50.0,control,therapeutic,15,8,,,0.03550282872,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,metronidazole,378,281,,,0.000333838594497,1.0,intervention.Variation,comparator.Variation,superior,superior,1
25486992,2015,sustained,5,5,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,50.0,50.0,control,therapeutic,15,8,,,0.03550282872,1.0,NCT00350298-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,101,therapeutic,Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) [ Time Frame: Day 0 to Day 84 ],positive,participants,7,,,x,NCT00350298,Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00350298,7,control,normal saline,99,74,,,1.0,8.109741066219999e-25,intervention.Specific,control,superior,inferior,0
25486992,2015,sustained,5,5,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,50.0,50.0,control,therapeutic,15,8,,,0.03550282872,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,Placebo + Standard of Care,378,281,,,0.000333838594497,1.0,intervention.Variation,control,superior,superior,1
25486992,2015,sustained,5,5,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,50.0,50.0,control,therapeutic,10,1,,,0.000475862810605,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,vancomycin,378,281,,,0.000333838594497,1.0,intervention.Variation,comparator.Variation,superior,superior,1
25486992,2015,sustained,5,5,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,50.0,50.0,control,therapeutic,10,1,,,0.000475862810605,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,vancomycin + metronidazole,378,281,,,0.000333838594497,1.0,intervention.Variation,comparator.Variation,superior,superior,1
25486992,2015,sustained,5,5,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,50.0,50.0,control,therapeutic,10,1,,,0.000475862810605,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,metronidazole,378,281,,,0.000333838594497,1.0,intervention.Variation,comparator.Variation,superior,superior,1
25486992,2015,sustained,5,5,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,50.0,50.0,control,therapeutic,10,1,,,0.000475862810605,1.0,NCT00350298-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,101,therapeutic,Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) [ Time Frame: Day 0 to Day 84 ],positive,participants,7,,,x,NCT00350298,Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00350298,7,control,normal saline,99,74,,,1.0,8.109741066219999e-25,intervention.Specific,control,superior,inferior,0
25486992,2015,sustained,5,5,positive,,C57BL/6,,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",survival,therapeutic,27.0,UK1,actoxumab-bezlotoxumab,49.0,,100000.0,,spores,50.0,50.0,control,therapeutic,10,1,,,0.000475862810605,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,Placebo + Standard of Care,378,281,,,0.000333838594497,1.0,intervention.Variation,control,superior,superior,1
18848941,2008,sustained,12,5,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,63.0,,10000.0,CFU,,50.0,50.0,control,therapeutic,12,6,,,0.999880020997,0.419409871101,NCT02951702-1,sustained,125.0,,125,mg,QD,,unspecified duration,antibiotic,vancomycin,no,17,prophylactic,Clostridium Difficile Infection Occurrence [ Time Frame: Within 4 weeks from the completion of antibiotic treatment ],positive,participants,0,,,x,NCT02951702,Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics,All,Older Adult,65 Years and older Â (Older Adult),Phase 4,https://ClinicalTrials.gov/show/NCT02951702,17,control,historical control,34,32,,,0.220012614027,0.999999999994,intervention.Specific,control,inconclusive,inconclusive,1
16966409,2006,sustained,15,4,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,MDX1388,,75.0,140000.0,CFU,spores,20.0,80.0,control,therapeutic,82,18,,,0.600847613604,0.9998500105,NCT01513239-1,sustained,10.0,10.0,10,mg/kg,QD,1.0,,antibody,MDX1388,no,390,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,14.9,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,332,control,vancomycin,378,281,,,0.000109233478458,1.0,intervention.Variation,comparator.Variation,inconclusive,superior,0
16966409,2006,sustained,15,4,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,MDX1388,,75.0,140000.0,CFU,spores,20.0,80.0,control,therapeutic,82,18,,,0.600847613604,0.9998500105,NCT01513239-1,sustained,10.0,10.0,10,mg/kg,QD,1.0,,antibody,MDX1388,no,390,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,14.9,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,332,control,vancomycin + metronidazole,378,281,,,0.000109233478458,1.0,intervention.Variation,comparator.Variation,inconclusive,superior,0
16966409,2006,sustained,15,4,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,MDX1388,,75.0,140000.0,CFU,spores,20.0,80.0,control,therapeutic,82,18,,,0.600847613604,0.9998500105,NCT01513239-1,sustained,10.0,10.0,10,mg/kg,QD,1.0,,antibody,MDX1388,no,390,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,14.9,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,332,control,metronidazole,378,281,,,0.000109233478458,1.0,intervention.Variation,comparator.Variation,inconclusive,superior,0
16966409,2006,sustained,15,4,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,MDX1388,,75.0,140000.0,CFU,spores,20.0,80.0,control,therapeutic,82,18,,,0.600847613604,0.9998500105,NCT01513239-1,sustained,10.0,10.0,10,mg/kg,QD,1.0,,antibody,MDX1388,no,390,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,14.9,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,332,control,Placebo + Standard of Care,378,281,,,0.000109233478458,1.0,intervention.Variation,control,inconclusive,superior,0
16966409,2006,sustained,22,15,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,CDA1 + MDX1388,,75.0,140000.0,CFU,spores,80.0,320.0,control,therapeutic,82,18,,,0.00013250375329,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,CDA1 + MDX1388,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,vancomycin,378,281,,,0.000333838594497,1.0,intervention.Variation,comparator.Variation,superior,superior,1
16966409,2006,sustained,22,15,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,CDA1 + MDX1388,,75.0,140000.0,CFU,spores,80.0,320.0,control,therapeutic,82,18,,,0.00013250375329,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,CDA1 + MDX1388,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,vancomycin + metronidazole,378,281,,,0.000333838594497,1.0,intervention.Variation,comparator.Variation,superior,superior,1
16966409,2006,sustained,22,15,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,CDA1 + MDX1388,,75.0,140000.0,CFU,spores,80.0,320.0,control,therapeutic,82,18,,,0.00013250375329,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,CDA1 + MDX1388,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,metronidazole,378,281,,,0.000333838594497,1.0,intervention.Variation,comparator.Variation,superior,superior,1
16966409,2006,sustained,22,15,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,CDA1 + MDX1388,,75.0,140000.0,CFU,spores,80.0,320.0,control,therapeutic,82,18,,,0.00013250375329,1.0,NCT00350298-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,CDA1 + MDX1388,no,101,therapeutic,Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) [ Time Frame: Day 0 to Day 84 ],positive,participants,7,,,x,NCT00350298,Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00350298,7,control,normal saline,99,74,,,1.0,8.109741066219999e-25,intervention.Specific,control,superior,inferior,0
16966409,2006,sustained,22,15,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,CDA1 + MDX1388,,75.0,140000.0,CFU,spores,80.0,320.0,control,therapeutic,82,18,,,0.00013250375329,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,CDA1 + MDX1388,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,control,Placebo + Standard of Care,378,281,,,0.000333838594497,1.0,intervention.Variation,control,superior,superior,1
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,3,0.3,1.5,0.388331952824,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,3,0.3,1.5,0.388331952824,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,3,0.3,1.5,0.388331952824,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,3,0.3,1.5,0.388331952824,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,12.5,62.5,1.0,0.00175827775963,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,12.5,62.5,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,12.5,62.5,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,12.5,62.5,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,25.0,125.0,1.0,0.00175827775963,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,25.0,125.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,25.0,125.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,25.0,125.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,3.0,15.0,1.0,0.00175827775963,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,3.0,15.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,3.0,15.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,3.0,15.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,30.0,150.0,1.0,0.00175827775963,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,30.0,150.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,30.0,150.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,30.0,150.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,300.0,1500.0,1.0,0.00175827775963,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,300.0,1500.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,300.0,1500.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,10,300.0,1500.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,3,0.3,1.5,1.41633769618e-05,1.0,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,3,0.3,1.5,1.41633769618e-05,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,3,0.3,1.5,1.41633769618e-05,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,3,0.3,1.5,1.41633769618e-05,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900004502,0.999900004502,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900004502,0.999900004502,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900004502,0.999900004502,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900004502,0.999900004502,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900004502,0.999900004502,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999800058987,0.999800058987,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999800058987,0.999800058987,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999800058987,0.999800058987,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999800058987,0.999800058987,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,3,0.3,1.5,0.000436404918425,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,20,20,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,1,0.2,1.0,0.0392421830117,1.0,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,1,0.2,1.0,0.0392421830117,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,1,0.2,1.0,0.0392421830117,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,1,0.2,1.0,0.0392421830117,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,17,15,2.0,10.0,1.0,0.00639934161031,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,17,15,2.0,10.0,1.0,0.00639934161031,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,17,15,2.0,10.0,1.0,0.00639934161031,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,17,15,2.0,10.0,1.0,0.00639934161031,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,11,20.0,100.0,1.0,0.00856860054545,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,11,20.0,100.0,1.0,0.00856860054545,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,11,20.0,100.0,1.0,0.00856860054545,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,11,20.0,100.0,1.0,0.00856860054545,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,1,0.2,1.0,2.14731573705e-10,1.0,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,1,0.2,1.0,2.14731573705e-10,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,1,0.2,1.0,2.14731573705e-10,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,1,0.2,1.0,2.14731573705e-10,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,17,15,2.0,10.0,0.124228405061,1.0,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,17,15,2.0,10.0,0.124228405061,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,17,15,2.0,10.0,0.124228405061,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,17,15,2.0,10.0,0.124228405061,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,11,20.0,100.0,1.0,0.472259035631,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,11,20.0,100.0,1.0,0.472259035631,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,11,20.0,100.0,1.0,0.472259035631,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,11,20.0,100.0,1.0,0.472259035631,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,1,0.2,1.0,1.61382896545e-14,1.0,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,1,0.2,1.0,1.61382896545e-14,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,1,0.2,1.0,1.61382896545e-14,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,1,0.2,1.0,1.61382896545e-14,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,17,15,2.0,10.0,0.00633219757552,1.0,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,17,15,2.0,10.0,0.00633219757552,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,17,15,2.0,10.0,0.00633219757552,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,17,15,2.0,10.0,0.00633219757552,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,11,20.0,100.0,0.9998900055,0.9998900055,NCT01987895-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,83.8 (79.2 to 87.5) ,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,antibiotic,vancomycin,318,270,500.0,5000.0,0.996994100158,0.392519908427,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,11,20.0,100.0,0.9998900055,0.9998900055,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.319058917443,0.999830050989,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,11,20.0,100.0,0.9998900055,0.9998900055,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,vancomycin,22,19,500.0,5000.0,0.410568418082,0.999800062986,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,11,20.0,100.0,0.9998900055,0.9998900055,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,vancomycin,22,19,500.0,5000.0,0.999810058887,0.466658295053,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,10.0,50.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,10.0,50.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,10.0,50.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,10.0,50.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,10.0,50.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,10.0,50.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,100.0,500.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,100.0,500.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,100.0,500.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,100.0,500.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,100.0,500.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,100.0,500.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,12.5,62.5,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,12.5,62.5,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,12.5,62.5,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,12.5,62.5,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,12.5,62.5,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,12.5,62.5,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,25.0,125.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,25.0,125.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,25.0,125.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,25.0,125.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,25.0,125.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,25.0,125.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,3.0,15.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,3.0,15.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,3.0,15.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,3.0,15.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,3.0,15.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,3.0,15.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,20,30.0,150.0,1.0,8.13357301777e-05,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,20,30.0,150.0,1.0,8.13357301777e-05,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,20,30.0,150.0,1.0,8.13357301777e-05,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,20,30.0,150.0,1.0,8.13357301777e-05,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,20,30.0,150.0,1.0,8.13357301777e-05,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,20,30.0,150.0,1.0,8.13357301777e-05,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,300.0,1500.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,300.0,1500.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,300.0,1500.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,300.0,1500.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,300.0,1500.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,300.0,1500.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,50.0,250.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,50.0,250.0,1.0,0.00175827775963,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,50.0,250.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,50.0,250.0,1.0,0.00175827775963,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,50.0,250.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,50.0,250.0,1.0,0.00175827775963,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,0.3,1.5,8.13357301777e-05,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,0.3,1.5,8.13357301777e-05,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,0.3,1.5,8.13357301777e-05,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,0.3,1.5,8.13357301777e-05,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,0.3,1.5,8.13357301777e-05,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,0.3,1.5,8.13357301777e-05,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,110,2.0,10.0,1.0,1.21358799363e-17,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,110,2.0,10.0,1.0,1.21358799363e-17,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,110,2.0,10.0,1.0,1.21358799363e-17,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,110,2.0,10.0,1.0,1.21358799363e-17,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,110,2.0,10.0,1.0,1.21358799363e-17,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,110,2.0,10.0,1.0,1.21358799363e-17,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,4.03673961167e-20,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,4.03673961167e-20,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,4.03673961167e-20,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,4.03673961167e-20,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,4.03673961167e-20,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,50,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,4.03673961167e-20,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,50,0.2,1.0,1.21358799363e-17,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,50,0.2,1.0,1.21358799363e-17,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,50,0.2,1.0,1.21358799363e-17,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,50,0.2,1.0,1.21358799363e-17,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,50,0.2,1.0,1.21358799363e-17,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,50,0.2,1.0,1.21358799363e-17,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,0.0274617592562,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,0.0274617592562,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,0.0274617592562,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,0.0274617592562,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,0.0274617592562,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,114,110,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,0.0274617592562,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,50,0.2,1.0,4.03673961167e-20,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,50,0.2,1.0,4.03673961167e-20,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,50,0.2,1.0,4.03673961167e-20,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,50,0.2,1.0,4.03673961167e-20,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,50,0.2,1.0,4.03673961167e-20,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,50,0.2,1.0,4.03673961167e-20,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,114,110,2.0,10.0,0.0274617592562,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.389441251138,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,114,110,2.0,10.0,0.0274617592562,1.0,NCT01222702-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.285822379242,0.999830045894,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,114,110,2.0,10.0,0.0274617592562,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830047591,0.389441251138,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,114,110,2.0,10.0,0.0274617592562,1.0,NCT01222702-4,acute,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,18,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.354791545336,0.999810055089,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,114,110,2.0,10.0,0.0274617592562,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830045894,0.285822379242,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,107,107,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,114,110,2.0,10.0,0.0274617592562,1.0,NCT01222702-7,acute,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,16,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999810055089,0.354791545336,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,0.3,1.5,0.999900014499,0.388331952824,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,0.3,1.5,0.999900014499,0.388331952824,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,0.3,1.5,0.999900014499,0.388331952824,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,0.3,1.5,0.999900014499,0.388331952824,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,10.0,50.0,1.0,0.000436404918425,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,10.0,50.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,10.0,50.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,10.0,50.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,100.0,500.0,1.0,0.000436404918425,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,100.0,500.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,100.0,500.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,100.0,500.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,12.5,62.5,1.0,0.000436404918425,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,12.5,62.5,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,12.5,62.5,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,12.5,62.5,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,25.0,125.0,1.0,0.000436404918425,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,25.0,125.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,25.0,125.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,25.0,125.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,3.0,15.0,1.0,0.000436404918425,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,3.0,15.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,3.0,15.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,3.0,15.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,20,30.0,150.0,1.0,1.41633769618e-05,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,20,30.0,150.0,1.0,1.41633769618e-05,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,20,30.0,150.0,1.0,1.41633769618e-05,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,20,30.0,150.0,1.0,1.41633769618e-05,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,300.0,1500.0,1.0,0.000436404918425,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,300.0,1500.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,300.0,1500.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,300.0,1500.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,50.0,250.0,1.0,0.000436404918425,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,50.0,250.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,50.0,250.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,10,50.0,250.0,1.0,0.000436404918425,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,0.3,1.5,0.00175827775963,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,10,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,0.3,1.5,8.13357301777e-05,1.0,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,0.3,1.5,8.13357301777e-05,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,0.3,1.5,8.13357301777e-05,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,0.3,1.5,8.13357301777e-05,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900004502,0.999900004502,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,10.0,50.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900004502,0.999900004502,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,100.0,500.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900004502,0.999900004502,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,12.5,62.5,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900004502,0.999900004502,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,25.0,125.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900004502,0.999900004502,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,3.0,15.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999800058987,0.999800058987,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999800058987,0.999800058987,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999800058987,0.999800058987,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,20,20,30.0,150.0,0.999800058987,0.999800058987,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900004502,0.999900004502,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,300.0,1500.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900004502,0.999900004502,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,10,50.0,250.0,0.999900004502,0.999900004502,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,50,0.2,1.0,1.0,0.0392421830117,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,50,0.2,1.0,1.0,0.0392421830117,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,50,0.2,1.0,1.0,0.0392421830117,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,50,0.2,1.0,1.0,0.0392421830117,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,110,2.0,10.0,1.0,2.14731573705e-10,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,110,2.0,10.0,1.0,2.14731573705e-10,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,110,2.0,10.0,1.0,2.14731573705e-10,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,110,2.0,10.0,1.0,2.14731573705e-10,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,1.61382896545e-14,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,1.61382896545e-14,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,1.61382896545e-14,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,1.61382896545e-14,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,17,15,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,50,0.2,1.0,0.00639934161031,1.0,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,17,15,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,50,0.2,1.0,0.00639934161031,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,17,15,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,50,0.2,1.0,0.00639934161031,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,17,15,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,50,0.2,1.0,0.00639934161031,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,17,15,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,114,110,2.0,10.0,1.0,0.124228405061,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,17,15,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,114,110,2.0,10.0,1.0,0.124228405061,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,17,15,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,114,110,2.0,10.0,1.0,0.124228405061,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,17,15,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,114,110,2.0,10.0,1.0,0.124228405061,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,17,15,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,0.00633219757552,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,17,15,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,0.00633219757552,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,17,15,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,0.00633219757552,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,17,15,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,107,20.0,100.0,1.0,0.00633219757552,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,acute,11,11,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,50,0.2,1.0,0.00856860054545,1.0,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,11,11,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,50,0.2,1.0,0.00856860054545,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,11,11,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,50,0.2,1.0,0.00856860054545,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,11,11,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,50,0.2,1.0,0.00856860054545,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,acute,11,11,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,114,110,2.0,10.0,0.472259035631,1.0,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,11,11,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,114,110,2.0,10.0,0.472259035631,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,11,11,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,114,110,2.0,10.0,0.472259035631,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,11,11,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,114,110,2.0,10.0,0.472259035631,1.0,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,11,11,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,107,20.0,100.0,0.9998900055,0.9998900055,NCT01987895-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,85.2 (80.9 to 88.7) ,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,antibiotic,Cadazolid,302,253,500.0,5000.0,0.392519908427,0.996994100158,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,11,11,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,107,20.0,100.0,0.9998900055,0.9998900055,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,17,16,500.0,5000.0,0.999830050989,0.319058917443,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,11,11,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,107,20.0,100.0,0.9998900055,0.9998900055,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,20,18,1000.0,10000.0,0.999800062986,0.410568418082,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,acute,11,11,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,107,20.0,100.0,0.9998900055,0.9998900055,NCT01222702-10,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,19,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,antibiotic,Cadazolid,19,16,2000.0,20000.0,0.466658295053,0.999810058887,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,0,0.3,1.5,0.107486680346,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,0,0.3,1.5,0.107486680346,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,0,0.3,1.5,0.107486680346,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,0,0.3,1.5,0.107486680346,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,3,12.5,62.5,0.999900014499,0.370138656809,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,3,12.5,62.5,0.999900014499,0.370138656809,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,3,12.5,62.5,0.999900014499,0.370138656809,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,3,12.5,62.5,0.999900014499,0.370138656809,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.261720657541,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.261720657541,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.261720657541,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.261720657541,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,6,3.0,15.0,1.0,0.0474390013112,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,6,3.0,15.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,6,3.0,15.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,6,3.0,15.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.00590896606444,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.00590896606444,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.00590896606444,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.00590896606444,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.00590896606444,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.00590896606444,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.00590896606444,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.00590896606444,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,20,20,50.0,250.0,1.0,1.49843010262e-06,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,20,20,50.0,250.0,1.0,1.49843010262e-06,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,20,20,50.0,250.0,1.0,1.49843010262e-06,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,vancomycin,therapeutic,20,20,50.0,250.0,1.0,1.49843010262e-06,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,0,0.3,1.5,0.0210952758787,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,0,0.3,1.5,0.0210952758787,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,0,0.3,1.5,0.0210952758787,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,0,0.3,1.5,0.0210952758787,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,3,12.5,62.5,0.388331952824,0.999900014499,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,3,12.5,62.5,0.388331952824,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,3,12.5,62.5,0.388331952824,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,3,12.5,62.5,0.388331952824,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.999900014499,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.261737330727,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.261737330727,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.261737330727,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.261737330727,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0474390013112,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0474390013112,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,0,0.3,1.5,0.000105857849119,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,0,0.3,1.5,0.000105857849119,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,0,0.3,1.5,0.000105857849119,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,0,0.3,1.5,0.000105857849119,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,3,12.5,62.5,0.020694732666,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,3,12.5,62.5,0.020694732666,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,3,12.5,62.5,0.020694732666,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,3,12.5,62.5,0.020694732666,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,4,25.0,125.0,0.0474390013112,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,4,25.0,125.0,0.0474390013112,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,4,25.0,125.0,0.0474390013112,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,4,25.0,125.0,0.0474390013112,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,6,3.0,15.0,0.261720657541,0.999900014499,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,6,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,6,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,6,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,8,30.0,150.0,0.999900014499,0.999900014499,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,8,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,8,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,8,30.0,150.0,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,8,300.0,1500.0,0.999900014499,0.999900014499,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,8,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,8,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,10,8,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,0.0375255410354,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,0.0375255410354,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,0.0375255410354,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,0.0375255410354,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,0,0.3,1.5,0.0210952758787,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,0,0.3,1.5,0.0210952758787,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,0,0.3,1.5,0.0210952758787,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,0,0.3,1.5,0.0210952758787,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,3,12.5,62.5,0.388331952824,0.999900014499,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,3,12.5,62.5,0.388331952824,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,3,12.5,62.5,0.388331952824,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,3,12.5,62.5,0.388331952824,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.999900014499,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.261737330727,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.261737330727,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.261737330727,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.261737330727,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0474390013112,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0474390013112,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,0,0.3,1.5,0.00175827775963,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,0,0.3,1.5,0.00175827775963,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,0,0.3,1.5,0.00175827775963,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,0,0.3,1.5,0.00175827775963,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,3,12.5,62.5,0.131673812866,0.999999995501,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,3,12.5,62.5,0.131673812866,0.999999995501,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,3,12.5,62.5,0.131673812866,0.999999995501,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,3,12.5,62.5,0.131673812866,0.999999995501,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,4,25.0,125.0,0.261737330727,0.999900014499,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,4,25.0,125.0,0.261737330727,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,4,25.0,125.0,0.261737330727,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,4,25.0,125.0,0.261737330727,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.999900014499,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,8,30.0,150.0,0.999900014499,0.261720657541,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,8,30.0,150.0,0.999900014499,0.261720657541,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,8,30.0,150.0,0.999900014499,0.261720657541,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,8,30.0,150.0,0.999900014499,0.261720657541,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,8,300.0,1500.0,0.999900014499,0.261720657541,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,8,300.0,1500.0,0.999900014499,0.261720657541,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,8,300.0,1500.0,0.999900014499,0.261720657541,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,10,8,300.0,1500.0,0.999900014499,0.261720657541,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,0.00216223881829,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,0.00216223881829,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,0.00216223881829,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,0.00216223881829,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,0,0.3,1.5,0.107486680346,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,0,0.3,1.5,0.107486680346,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,0,0.3,1.5,0.107486680346,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,0,0.3,1.5,0.107486680346,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,3,12.5,62.5,0.999900014499,0.370138656809,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,3,12.5,62.5,0.999900014499,0.370138656809,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,3,12.5,62.5,0.999900014499,0.370138656809,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,3,12.5,62.5,0.999900014499,0.370138656809,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.261720657541,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.261720657541,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.261720657541,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.261720657541,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,6,3.0,15.0,1.0,0.0474390013112,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,6,3.0,15.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,6,3.0,15.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,6,3.0,15.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.00590896606444,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.00590896606444,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.00590896606444,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.00590896606444,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.00590896606444,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.00590896606444,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.00590896606444,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.00590896606444,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,1.49843010262e-06,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,1.49843010262e-06,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,1.49843010262e-06,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,1.49843010262e-06,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,0,0.3,1.5,0.00441906200792,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,0,0.3,1.5,0.00441906200792,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,0,0.3,1.5,0.00441906200792,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,0,0.3,1.5,0.00441906200792,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,3,12.5,62.5,0.182259007148,0.999999999999,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,3,12.5,62.5,0.182259007148,0.999999999999,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,3,12.5,62.5,0.182259007148,0.999999999999,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,3,12.5,62.5,0.182259007148,0.999999999999,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,4,25.0,125.0,0.392509333833,0.999900024496,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,4,25.0,125.0,0.392509333833,0.999900024496,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,4,25.0,125.0,0.392509333833,0.999900024496,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,4,25.0,125.0,0.392509333833,0.999900024496,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900024496,0.392509333833,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900024496,0.392509333833,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900024496,0.392509333833,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900024496,0.392509333833,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0680474159381,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0680474159381,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0680474159381,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0680474159381,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0680474159381,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0680474159381,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0680474159381,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0680474159381,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,9.63072634272e-05,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,9.63072634272e-05,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,9.63072634272e-05,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,9.63072634272e-05,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,0,0.3,1.5,0.00175827775963,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,0,0.3,1.5,0.00175827775963,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,0,0.3,1.5,0.00175827775963,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,0,0.3,1.5,0.00175827775963,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,3,12.5,62.5,0.131673812866,0.999999995501,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,3,12.5,62.5,0.131673812866,0.999999995501,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,3,12.5,62.5,0.131673812866,0.999999995501,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,3,12.5,62.5,0.131673812866,0.999999995501,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,4,25.0,125.0,0.261737330727,0.999900014499,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,4,25.0,125.0,0.261737330727,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,4,25.0,125.0,0.261737330727,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,4,25.0,125.0,0.261737330727,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.999900014499,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,8,30.0,150.0,0.999900014499,0.261720657541,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,8,30.0,150.0,0.999900014499,0.261720657541,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,8,30.0,150.0,0.999900014499,0.261720657541,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,8,30.0,150.0,0.999900014499,0.261720657541,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,8,300.0,1500.0,0.999900014499,0.261720657541,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,8,300.0,1500.0,0.999900014499,0.261720657541,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,8,300.0,1500.0,0.999900014499,0.261720657541,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,10,8,300.0,1500.0,0.999900014499,0.261720657541,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,0.00216223881829,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,0.00216223881829,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,0.00216223881829,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,0.00216223881829,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,0,0.3,1.5,0.0210952758787,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,0,0.3,1.5,0.0210952758787,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,0,0.3,1.5,0.0210952758787,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,0,0.3,1.5,0.0210952758787,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,3,12.5,62.5,0.388331952824,0.999900014499,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,3,12.5,62.5,0.388331952824,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,3,12.5,62.5,0.388331952824,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,3,12.5,62.5,0.388331952824,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.999900014499,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,4,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.261737330727,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.261737330727,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.261737330727,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,6,3.0,15.0,0.999900014499,0.261737330727,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0474390013112,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,8,30.0,150.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0474390013112,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,10,8,300.0,1500.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,vancomycin,therapeutic,20,20,50.0,250.0,1.0,8.13357301777e-05,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,1,0.2,1.0,0.0479804688203,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,1,0.2,1.0,0.0479804688203,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,1,0.2,1.0,0.0479804688203,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,1,0.2,1.0,0.0479804688203,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,17,12,2.0,10.0,1.0,0.0582873352162,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,17,12,2.0,10.0,1.0,0.0582873352162,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,17,12,2.0,10.0,1.0,0.0582873352162,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,17,12,2.0,10.0,1.0,0.0582873352162,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,9,20.0,100.0,1.0,0.0387202216319,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,9,20.0,100.0,1.0,0.0387202216319,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,9,20.0,100.0,1.0,0.0387202216319,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,vancomycin,therapeutic,11,9,20.0,100.0,1.0,0.0387202216319,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,1,0.2,1.0,4.54467692122e-07,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,1,0.2,1.0,4.54467692122e-07,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,1,0.2,1.0,4.54467692122e-07,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,1,0.2,1.0,4.54467692122e-07,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,17,12,2.0,10.0,0.0187720980207,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,17,12,2.0,10.0,0.0187720980207,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,17,12,2.0,10.0,0.0187720980207,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,17,12,2.0,10.0,0.0187720980207,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,9,20.0,100.0,0.176380179482,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,9,20.0,100.0,0.176380179482,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,9,20.0,100.0,0.176380179482,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,vancomycin,therapeutic,11,9,20.0,100.0,0.176380179482,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,1,0.2,1.0,1.09880868413e-05,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,1,0.2,1.0,1.09880868413e-05,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,1,0.2,1.0,1.09880868413e-05,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,1,0.2,1.0,1.09880868413e-05,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,17,12,2.0,10.0,0.0613392867623,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,17,12,2.0,10.0,0.0613392867623,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,17,12,2.0,10.0,0.0613392867623,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,17,12,2.0,10.0,0.0613392867623,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,9,20.0,100.0,0.454055271398,1.0,NCT01987895-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,65.6 (60.0 to 70.7),Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,vancomycin,318,198,500.0,5000.0,0.255727789307,0.996994114522,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,9,20.0,100.0,0.454055271398,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,vancomycin,22,12,500.0,5000.0,0.0956457131077,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,9,20.0,100.0,0.454055271398,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,vancomycin,22,12,500.0,5000.0,0.244436458793,0.999999976908,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,vancomycin,therapeutic,11,9,20.0,100.0,0.454055271398,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,vancomycin,22,12,500.0,5000.0,0.512835453931,0.999820015303,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,10.0,50.0,0.999900014499,0.261720657541,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,10.0,50.0,0.999900014499,0.261720657541,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,10.0,50.0,0.999900014499,0.261720657541,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,10.0,50.0,0.999900014499,0.261720657541,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,10.0,50.0,0.999900014499,0.261720657541,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,10.0,50.0,0.999900014499,0.261720657541,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.00590896606444,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.00590896606444,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.00590896606444,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.00590896606444,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.00590896606444,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.00590896606444,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.261720657541,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.261720657541,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.261720657541,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.261720657541,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.261720657541,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.261720657541,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.0680474159381,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.0680474159381,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.0680474159381,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.0680474159381,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.0680474159381,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.0680474159381,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.261720657541,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.261720657541,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.261720657541,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.261720657541,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.261720657541,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.261720657541,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,10.0,50.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.00590896606444,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.00590896606444,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.00590896606444,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.00590896606444,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.00590896606444,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.00590896606444,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.0474390013112,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.0474390013112,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.0474390013112,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.0474390013112,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.0474390013112,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.0474390013112,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.0474390013112,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.0474390013112,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.0474390013112,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.0474390013112,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.0474390013112,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.0474390013112,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.261720657541,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.261720657541,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.261720657541,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.261720657541,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.261720657541,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.261720657541,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.00590896606444,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.00590896606444,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.00590896606444,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.00590896606444,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.00590896606444,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.00590896606444,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.0680474159381,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.0680474159381,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.0680474159381,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.0680474159381,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.0680474159381,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.0680474159381,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.261720657541,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.261720657541,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.261720657541,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.261720657541,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.261720657541,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.261720657541,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.0474390013112,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.0474390013112,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.0474390013112,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.0474390013112,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.0474390013112,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,100.0,500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.0474390013112,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.392509333833,0.999900024496,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.392509333833,0.999900024496,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.392509333833,0.999900024496,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.392509333833,0.999900024496,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.392509333833,0.999900024496,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.392509333833,0.999900024496,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.00590896606444,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.00590896606444,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.00590896606444,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.00590896606444,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.00590896606444,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.00590896606444,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.0680474159381,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.0680474159381,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.0680474159381,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.0680474159381,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.0680474159381,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.0680474159381,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.261720657541,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.261720657541,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.261720657541,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.261720657541,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.261720657541,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.261720657541,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900024496,0.392509333833,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900024496,0.392509333833,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900024496,0.392509333833,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900024496,0.392509333833,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900024496,0.392509333833,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900024496,0.392509333833,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.392509333833,0.999900024496,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.392509333833,0.999900024496,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.392509333833,0.999900024496,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.392509333833,0.999900024496,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.392509333833,0.999900024496,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,20,10,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.392509333833,0.999900024496,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,1.89961321771e-17,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,1.89961321771e-17,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,1.89961321771e-17,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,1.89961321771e-17,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,1.89961321771e-17,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,1.89961321771e-17,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,6.450359193039999e-14,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,6.450359193039999e-14,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,6.450359193039999e-14,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,6.450359193039999e-14,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,6.450359193039999e-14,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,107,43,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,6.450359193039999e-14,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,43,0.2,1.0,1.89961321771e-17,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,43,0.2,1.0,1.89961321771e-17,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,43,0.2,1.0,1.89961321771e-17,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,43,0.2,1.0,1.89961321771e-17,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,43,0.2,1.0,1.89961321771e-17,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,43,0.2,1.0,1.89961321771e-17,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,94,20.0,100.0,0.169323468515,0.999999433942,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,94,20.0,100.0,0.169323468515,0.999999433942,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,94,20.0,100.0,0.169323468515,0.999999433942,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,94,20.0,100.0,0.169323468515,0.999999433942,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,94,20.0,100.0,0.169323468515,0.999999433942,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,114,105,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,94,20.0,100.0,0.169323468515,0.999999433942,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,43,0.2,1.0,6.450359193039999e-14,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.38951942159,0.999830047591,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,43,0.2,1.0,6.450359193039999e-14,1.0,NCT01222702-13,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,13,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.124657002729,0.999999986404,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,43,0.2,1.0,6.450359193039999e-14,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999830047591,0.38951942159,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,43,0.2,1.0,6.450359193039999e-14,1.0,NCT01222702-16,sustained,1000.0,10000.0,500,mg,BID,10.0,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,14,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.284700044892,0.999820051293,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,43,0.2,1.0,6.450359193039999e-14,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999986404,0.124657002729,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,107,94,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,Cadazolid,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,43,0.2,1.0,6.450359193039999e-14,1.0,NCT01222702-19,sustained,2000.0,20000.0,1000,mg,BID,10.0,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,10,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999820051293,0.284700044892,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,2,0.3,1.5,1.0,0.107486680346,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,2,0.3,1.5,1.0,0.107486680346,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,2,0.3,1.5,1.0,0.107486680346,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,2,0.3,1.5,1.0,0.107486680346,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,10.0,50.0,1.0,0.0210952758787,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,10.0,50.0,1.0,0.0210952758787,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,10.0,50.0,1.0,0.0210952758787,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,10.0,50.0,1.0,0.0210952758787,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.000105857849119,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.000105857849119,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.000105857849119,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.000105857849119,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,12.5,62.5,1.0,0.0210952758787,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,12.5,62.5,1.0,0.0210952758787,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,12.5,62.5,1.0,0.0210952758787,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,12.5,62.5,1.0,0.0210952758787,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.00175827775963,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.00175827775963,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.00175827775963,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,25.0,125.0,1.0,0.00175827775963,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,2,3.0,15.0,1.0,0.107486680346,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,2,3.0,15.0,1.0,0.107486680346,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,2,3.0,15.0,1.0,0.107486680346,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,2,3.0,15.0,1.0,0.107486680346,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.00441906200792,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.00441906200792,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.00441906200792,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,20,10,30.0,150.0,1.0,0.00441906200792,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.00175827775963,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.00175827775963,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.00175827775963,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,6,300.0,1500.0,1.0,0.00175827775963,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,50.0,250.0,1.0,0.0210952758787,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,50.0,250.0,1.0,0.0210952758787,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,50.0,250.0,1.0,0.0210952758787,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,0.3,1.5,Cadazolid,therapeutic,10,4,50.0,250.0,1.0,0.0210952758787,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,2,0.3,1.5,0.370138656809,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,2,0.3,1.5,0.370138656809,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,2,0.3,1.5,0.370138656809,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,2,0.3,1.5,0.370138656809,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,10.0,50.0,0.999900014499,0.388331952824,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,10.0,50.0,0.999900014499,0.388331952824,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,10.0,50.0,0.999900014499,0.388331952824,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,10.0,50.0,0.999900014499,0.388331952824,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.020694732666,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.020694732666,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.020694732666,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.020694732666,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.388331952824,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.388331952824,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.388331952824,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.388331952824,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,25.0,125.0,0.999999995501,0.131673812866,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,25.0,125.0,0.999999995501,0.131673812866,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,25.0,125.0,0.999999995501,0.131673812866,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,25.0,125.0,0.999999995501,0.131673812866,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.370138656809,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.370138656809,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.370138656809,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,2,3.0,15.0,0.370138656809,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,10,30.0,150.0,0.999999999999,0.182259007148,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,10,30.0,150.0,0.999999999999,0.182259007148,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,10,30.0,150.0,0.999999999999,0.182259007148,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,20,10,30.0,150.0,0.999999999999,0.182259007148,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999999995501,0.131673812866,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999999995501,0.131673812866,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999999995501,0.131673812866,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999999995501,0.131673812866,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.388331952824,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.388331952824,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.388331952824,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,12.5,62.5,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.388331952824,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.261720657541,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.999900014499,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,8,100.0,500.0,1.0,0.0474390013112,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.261737330727,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.999900024496,0.392509333833,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.261737330727,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,4,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,25.0,125.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.261737330727,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.261737330727,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.261737330727,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.261737330727,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.999900014499,0.261720657541,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.999900014499,0.261720657541,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.999900014499,0.261720657541,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.999900014499,0.261720657541,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.261737330727,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.261737330727,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.261737330727,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.261737330727,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.392509333833,0.999900024496,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.392509333833,0.999900024496,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.392509333833,0.999900024496,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.392509333833,0.999900024496,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,3.0,15.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.261737330727,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.00590896606444,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.00590896606444,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.00590896606444,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.00590896606444,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.0474390013112,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.999900014499,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.0474390013112,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.261720657541,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.00590896606444,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.00590896606444,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.00590896606444,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.00590896606444,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.0680474159381,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.0680474159381,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.0680474159381,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.0680474159381,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.261720657541,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.0474390013112,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,30.0,150.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.00590896606444,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.00590896606444,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.00590896606444,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,0.3,1.5,0.00590896606444,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.0474390013112,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,10.0,50.0,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.999900014499,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.999900014499,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.0474390013112,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,12.5,62.5,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.261720657541,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.00590896606444,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.00590896606444,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.00590896606444,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,2,3.0,15.0,0.00590896606444,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.0680474159381,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.0680474159381,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.0680474159381,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,20,10,30.0,150.0,0.0680474159381,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.261720657541,0.999900014499,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.261720657541,0.999900014499,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.0474390013112,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,10,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,300.0,1500.0,Cadazolid,therapeutic,10,4,50.0,250.0,0.0474390013112,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,2,0.3,1.5,1.49843010262e-06,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,2,0.3,1.5,1.49843010262e-06,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,2,0.3,1.5,1.49843010262e-06,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,2,0.3,1.5,1.49843010262e-06,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,10.0,50.0,8.13357301777e-05,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,10.0,50.0,8.13357301777e-05,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,10.0,50.0,8.13357301777e-05,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,10.0,50.0,8.13357301777e-05,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.0375255410354,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.0375255410354,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.0375255410354,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,8,100.0,500.0,0.0375255410354,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,12.5,62.5,8.13357301777e-05,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,12.5,62.5,8.13357301777e-05,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,12.5,62.5,8.13357301777e-05,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,12.5,62.5,8.13357301777e-05,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.00216223881829,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.00216223881829,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.00216223881829,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,6,25.0,125.0,0.00216223881829,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,2,3.0,15.0,1.49843010262e-06,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,2,3.0,15.0,1.49843010262e-06,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,2,3.0,15.0,1.49843010262e-06,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,2,3.0,15.0,1.49843010262e-06,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,20,10,30.0,150.0,9.63072634272e-05,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,20,10,30.0,150.0,9.63072634272e-05,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,20,10,30.0,150.0,9.63072634272e-05,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,20,10,30.0,150.0,9.63072634272e-05,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.00216223881829,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.00216223881829,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.00216223881829,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,6,300.0,1500.0,0.00216223881829,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,50.0,250.0,8.13357301777e-05,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,50.0,250.0,8.13357301777e-05,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,50.0,250.0,8.13357301777e-05,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,20,20,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,58.0,111.0,100000.0,CFU,spores,50.0,250.0,Cadazolid,therapeutic,10,4,50.0,250.0,8.13357301777e-05,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,43,0.2,1.0,1.0,0.0479804688203,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,43,0.2,1.0,1.0,0.0479804688203,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,43,0.2,1.0,1.0,0.0479804688203,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,43,0.2,1.0,1.0,0.0479804688203,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,4.54467692122e-07,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,4.54467692122e-07,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,4.54467692122e-07,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,4.54467692122e-07,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,1.09880868413e-05,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,1.09880868413e-05,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,1.09880868413e-05,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,11,1,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,0.2,1.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,1.09880868413e-05,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,17,12,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,43,0.2,1.0,0.0582873352162,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,17,12,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,43,0.2,1.0,0.0582873352162,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,17,12,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,43,0.2,1.0,0.0582873352162,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,17,12,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,43,0.2,1.0,0.0582873352162,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,17,12,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,0.0187720980207,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,17,12,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,0.0187720980207,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,17,12,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,0.0187720980207,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,17,12,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,0.0187720980207,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inferior,inconclusive,0
24277020,2014,sustained,17,12,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,0.0613392867623,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,17,12,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,0.0613392867623,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,17,12,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,0.0613392867623,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,17,12,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,2.0,10.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,0.0613392867623,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,11,9,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,43,0.2,1.0,0.0387202216319,1.0,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,11,9,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,43,0.2,1.0,0.0387202216319,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,11,9,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,43,0.2,1.0,0.0387202216319,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,11,9,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,43,0.2,1.0,0.0387202216319,1.0,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,superior,inconclusive,0
24277020,2014,sustained,11,9,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,0.176380179482,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,11,9,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,0.176380179482,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,11,9,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,0.176380179482,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,11,9,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,114,105,2.0,10.0,1.0,0.176380179482,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,11,9,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,0.454055271398,NCT01987895-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,62.3 (56.8 to 67.4),Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,antibiotic,Cadazolid,302,198,500.0,5000.0,0.996994114522,0.255727789307,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,11,9,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,0.454055271398,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,17,13,500.0,5000.0,0.999999999998,0.0956457131077,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,11,9,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,0.454055271398,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,20,14,1000.0,10000.0,0.999999976908,0.244436458793,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
24277020,2014,sustained,11,9,positive,,C57BL/6,F,mouse,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,70.0,,100000.0,CFU,spores,20.0,100.0,Cadazolid,therapeutic,107,94,20.0,100.0,1.0,0.454055271398,NCT01222702-22,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,12,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,antibiotic,Cadazolid,18,10,2000.0,20000.0,0.999820015303,0.512835453931,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,5,1.0,5.0,1.0,0.00638961791984,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,5,1.0,5.0,1.0,0.00638961791984,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,5,1.0,5.0,1.0,0.00638961791984,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,5,1.0,5.0,1.0,0.00638961791984,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,5,1.0,5.0,1.0,0.00638961791984,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,5,1.0,5.0,1.0,0.00638961791984,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,5,1.0,5.0,0.999900014499,0.261737155132,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,5,1.0,5.0,0.999900014499,0.261737155132,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,5,1.0,5.0,0.999900014499,0.261737155132,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,5,1.0,5.0,0.999900014499,0.261737155132,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,5,1.0,5.0,0.999900014499,0.261737155132,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,5,1.0,5.0,0.999900014499,0.261737155132,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,10,5.0,25.0,1.0,0.000436404918425,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,10,5.0,25.0,1.0,0.000436404918425,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,10,5.0,25.0,1.0,0.000436404918425,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,10,5.0,25.0,1.0,0.000436404918425,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,10,5.0,25.0,1.0,0.000436404918425,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,10,5.0,25.0,1.0,0.000436404918425,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.2,1.0,9.53674316308e-07,1.0,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.2,1.0,9.53674316308e-07,1.0,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.2,1.0,9.53674316308e-07,1.0,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.2,1.0,9.53674316308e-07,1.0,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.2,1.0,9.53674316308e-07,1.0,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.2,1.0,9.53674316308e-07,1.0,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,5,1.0,5.0,0.00638961791984,1.0,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,5,1.0,5.0,0.00638961791984,1.0,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,5,1.0,5.0,0.00638961791984,1.0,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,5,1.0,5.0,0.00638961791984,1.0,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,5,1.0,5.0,0.00638961791984,1.0,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,5,1.0,5.0,0.00638961791984,1.0,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.2,1.0,9.53674316308e-07,1.0,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.2,1.0,9.53674316308e-07,1.0,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.2,1.0,9.53674316308e-07,1.0,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.2,1.0,9.53674316308e-07,1.0,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.2,1.0,9.53674316308e-07,1.0,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.2,1.0,9.53674316308e-07,1.0,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,5,1.0,5.0,0.00638961791984,1.0,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,5,1.0,5.0,0.00638961791984,1.0,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,5,1.0,5.0,0.00638961791984,1.0,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,5,1.0,5.0,0.00638961791984,1.0,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,5,1.0,5.0,0.00638961791984,1.0,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,5,1.0,5.0,0.00638961791984,1.0,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,vancomycin,therapeutic,6,5,100.0,500.0,1.0,0.072998046875,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,vancomycin,therapeutic,6,5,100.0,500.0,1.0,0.072998046875,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,vancomycin,therapeutic,6,5,100.0,500.0,1.0,0.072998046875,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,vancomycin,therapeutic,6,5,100.0,500.0,1.0,0.072998046875,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,vancomycin,therapeutic,6,5,100.0,500.0,1.0,0.072998046875,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,vancomycin,therapeutic,6,5,100.0,500.0,1.0,0.072998046875,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.3,1.5,vancomycin,therapeutic,6,5,100.0,500.0,0.9999999985,0.151449263963,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.3,1.5,vancomycin,therapeutic,6,5,100.0,500.0,0.9999999985,0.151449263963,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.3,1.5,vancomycin,therapeutic,6,5,100.0,500.0,0.9999999985,0.151449263963,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.3,1.5,vancomycin,therapeutic,6,5,100.0,500.0,0.9999999985,0.151449263963,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.3,1.5,vancomycin,therapeutic,6,5,100.0,500.0,0.9999999985,0.151449263963,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.3,1.5,vancomycin,therapeutic,6,5,100.0,500.0,0.9999999985,0.151449263963,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,vancomycin,therapeutic,6,5,100.0,500.0,0.25903359665,0.9999999985,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,vancomycin,therapeutic,6,5,100.0,500.0,0.25903359665,0.9999999985,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,vancomycin,therapeutic,6,5,100.0,500.0,0.25903359665,0.9999999985,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,vancomycin,therapeutic,6,5,100.0,500.0,0.25903359665,0.9999999985,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,vancomycin,therapeutic,6,5,100.0,500.0,0.25903359665,0.9999999985,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,vancomycin,therapeutic,6,5,100.0,500.0,0.25903359665,0.9999999985,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,0.000436404918425,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,0.000436404918425,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,0.000436404918425,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,0.000436404918425,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,0.000436404918425,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,0.000436404918425,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,0.000436404918425,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,0.000436404918425,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,0.000436404918425,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,0.000436404918425,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,0.000436404918425,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,0.000436404918425,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,3,0.3,1.5,0.9999400051,0.38720703125,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,3,0.3,1.5,0.9999400051,0.38720703125,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,3,0.3,1.5,0.9999400051,0.38720703125,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,3,0.3,1.5,0.9999400051,0.38720703125,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,3,0.3,1.5,0.9999400051,0.38720703125,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,3,0.3,1.5,0.9999400051,0.38720703125,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,6,3.0,15.0,1.0,0.0105031653916,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,6,3.0,15.0,1.0,0.0105031653916,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,6,3.0,15.0,1.0,0.0105031653916,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,6,3.0,15.0,1.0,0.0105031653916,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,6,3.0,15.0,1.0,0.0105031653916,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,6,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,6,3.0,15.0,1.0,0.0105031653916,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.3,1.5,fidaxomicin,therapeutic,6,6,3.0,15.0,1.0,0.0337882737941,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.3,1.5,fidaxomicin,therapeutic,6,6,3.0,15.0,1.0,0.0337882737941,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.3,1.5,fidaxomicin,therapeutic,6,6,3.0,15.0,1.0,0.0337882737941,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.3,1.5,fidaxomicin,therapeutic,6,6,3.0,15.0,1.0,0.0337882737941,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.3,1.5,fidaxomicin,therapeutic,6,6,3.0,15.0,1.0,0.0337882737941,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.3,1.5,fidaxomicin,therapeutic,6,6,3.0,15.0,1.0,0.0337882737941,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,6,2,0.03,0.15,0.0105031653916,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,6,2,0.03,0.15,0.0105031653916,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,6,2,0.03,0.15,0.0105031653916,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,6,2,0.03,0.15,0.0105031653916,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,6,2,0.03,0.15,0.0105031653916,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,6,2,0.03,0.15,0.0105031653916,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,6,3,0.3,1.5,0.0337882737941,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,6,3,0.3,1.5,0.0337882737941,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,6,3,0.3,1.5,0.0337882737941,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,6,3,0.3,1.5,0.0337882737941,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,6,3,0.3,1.5,0.0337882737941,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,6,6,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,6,3,0.3,1.5,0.0337882737941,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,5,1,1.0,1.0,0.0107421875,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,5,1,1.0,1.0,0.0107421875,1.0,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,5,1,1.0,1.0,0.0107421875,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,5,1,1.0,1.0,0.0107421875,1.0,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,5,1,1.0,1.0,0.0107421875,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,5,1,1.0,1.0,0.0107421875,1.0,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,acute,5,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,fidaxomicin,therapeutic,5,5,2.0,10.0,1.0,0.0107421875,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,5,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,fidaxomicin,therapeutic,5,5,2.0,10.0,1.0,0.0107421875,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,fidaxomicin,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,5,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,fidaxomicin,therapeutic,5,5,2.0,10.0,1.0,0.0107421875,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,5,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,fidaxomicin,therapeutic,5,5,2.0,10.0,1.0,0.0107421875,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,5,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,fidaxomicin,therapeutic,5,5,2.0,10.0,1.0,0.0107421875,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,acute,5,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,fidaxomicin,therapeutic,5,5,2.0,10.0,1.0,0.0107421875,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,fidaxomicin,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,0.2,1.0,1.0,0.0437939533725,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,9.53674316308e-07,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,9.53674316308e-07,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inferior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.00638961791984,1.0,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.00638961791984,1.0,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.00638961791984,1.0,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.00638961791984,1.0,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.00638961791984,1.0,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.00638961791984,1.0,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,superior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.261737155132,0.999900014499,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.261737155132,0.999900014499,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.261737155132,0.999900014499,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.261737155132,0.999900014499,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.261737155132,0.999900014499,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.261737155132,0.999900014499,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,0.00638961791984,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,0.00638961791984,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,0.00638961791984,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,0.00638961791984,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,0.00638961791984,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,1.0,5.0,1.0,0.00638961791984,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inferior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,0.00638961791984,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,0.00638961791984,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,0.00638961791984,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,0.00638961791984,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,0.00638961791984,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,acute,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,10,5.0,25.0,1.0,0.00638961791984,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inferior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,9.53674316308e-07,1.0,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,0.2,1.0,0.000436404918425,1.0,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,superior,inconclusive,0
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,10,1.0,5.0,0.999900014499,0.999900014499,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,10,1.0,5.0,0.999900014499,0.999900014499,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,10,1.0,5.0,0.999900014499,0.999900014499,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,10,1.0,5.0,0.999900014499,0.999900014499,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,10,1.0,5.0,0.999900014499,0.999900014499,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,10,1.0,5.0,0.999900014499,0.999900014499,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,acute,10,10,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,2.0,10.0,0.999900014499,0.999900014499,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,2.0,10.0,0.999900014499,0.999900014499,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,2.0,10.0,0.999900014499,0.999900014499,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,2.0,10.0,0.999900014499,0.999900014499,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,2.0,10.0,0.999900014499,0.999900014499,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,2.0,10.0,0.999900014499,0.999900014499,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,2.0,10.0,0.999900014499,0.999900014499,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,2.0,10.0,0.999900014499,0.999900014499,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,2.0,10.0,0.999900014499,0.999900014499,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,2.0,10.0,0.999900014499,0.999900014499,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,2.0,10.0,0.999900014499,0.999900014499,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,2.0,10.0,0.999900014499,0.999900014499,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,10,5.0,25.0,0.999900014499,0.999900014499,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,2,0.03,0.15,0.072998046875,1.0,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,2,0.03,0.15,0.072998046875,1.0,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,2,0.03,0.15,0.072998046875,1.0,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,2,0.03,0.15,0.072998046875,1.0,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,2,0.03,0.15,0.072998046875,1.0,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,2,0.03,0.15,0.072998046875,1.0,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,3,0.3,1.5,0.151449263963,0.9999999985,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,3,0.3,1.5,0.151449263963,0.9999999985,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,3,0.3,1.5,0.151449263963,0.9999999985,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,3,0.3,1.5,0.151449263963,0.9999999985,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,3,0.3,1.5,0.151449263963,0.9999999985,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,3,0.3,1.5,0.151449263963,0.9999999985,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,6,3.0,15.0,0.9999999985,0.25903359665,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,fidaxomicin,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,6,3.0,15.0,0.9999999985,0.25903359665,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,fidaxomicin,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,6,3.0,15.0,0.9999999985,0.25903359665,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,fidaxomicin,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,6,3.0,15.0,0.9999999985,0.25903359665,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,fidaxomicin,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,6,3.0,15.0,0.9999999985,0.25903359665,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,fidaxomicin,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,acute,6,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,30000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,6,3.0,15.0,0.9999999985,0.25903359665,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,fidaxomicin,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inconclusive,superior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inconclusive,superior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,5,1.0,5.0,1.0,0.00638961791984,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,5,1.0,5.0,1.0,0.00638961791984,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,5,1.0,5.0,1.0,0.00638961791984,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inferior,superior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,5,1.0,5.0,1.0,0.00638961791984,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inferior,superior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inferior,superior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,vancomycin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inferior,superior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inconclusive,superior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,5,1.0,5.0,1.0,0.00638961791984,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,5,1.0,5.0,1.0,0.00638961791984,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,5,1.0,5.0,1.0,0.00638961791984,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inferior,superior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,5,1.0,5.0,1.0,0.00638961791984,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inferior,superior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inferior,superior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,vancomycin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inferior,superior,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,5,1.0,5.0,0.999900014499,0.261737155132,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,5,1.0,5.0,0.999900014499,0.261737155132,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,5,1.0,5.0,0.999900014499,0.261737155132,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,5,1.0,5.0,0.999900014499,0.261737155132,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inconclusive,superior,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,9,5.0,25.0,1.0,0.00397777557269,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,9,5.0,25.0,1.0,0.00397777557269,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,9,5.0,25.0,1.0,0.00397777557269,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inferior,superior,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,vancomycin,therapeutic,10,9,5.0,25.0,1.0,0.00397777557269,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inferior,superior,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.04,0.2,2.00271606436e-05,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.04,0.2,2.00271606436e-05,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.04,0.2,2.00271606436e-05,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.04,0.2,2.00271606436e-05,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.2,1.0,2.00271606436e-05,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.2,1.0,2.00271606436e-05,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.2,1.0,2.00271606436e-05,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,0,0.2,1.0,2.00271606436e-05,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,5,1.0,5.0,0.0311548075887,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,5,1.0,5.0,0.0311548075887,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,5,1.0,5.0,0.0311548075887,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,5,1.0,5.0,0.0311548075887,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,9,5.0,25.0,0.999900014499,0.999900014499,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,9,5.0,25.0,0.999900014499,0.999900014499,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,9,5.0,25.0,0.999900014499,0.999900014499,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,vancomycin,therapeutic,10,9,5.0,25.0,0.999900014499,0.999900014499,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inconclusive,superior,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,0,20.0,100.0,0.0437939533725,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,0,20.0,100.0,0.0437939533725,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,0,20.0,100.0,0.0437939533725,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,0,20.0,100.0,0.0437939533725,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,vancomycin,therapeutic,10,0,20.0,100.0,0.999900014499,0.999900014499,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,vancomycin,therapeutic,10,0,20.0,100.0,0.999900014499,0.999900014499,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,vancomycin,therapeutic,10,0,20.0,100.0,0.999900014499,0.999900014499,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,vancomycin,therapeutic,10,0,20.0,100.0,0.999900014499,0.999900014499,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inconclusive,superior,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,0,20.0,100.0,0.0210952758787,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,0,20.0,100.0,0.0210952758787,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,0,20.0,100.0,0.0210952758787,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,0,20.0,100.0,0.0210952758787,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,vancomycin,therapeutic,10,0,20.0,100.0,0.999900014499,0.999900014499,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,vancomycin,therapeutic,10,0,20.0,100.0,0.999900014499,0.999900014499,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,vancomycin,therapeutic,10,0,20.0,100.0,0.999900014499,0.999900014499,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,vancomycin,therapeutic,10,0,20.0,100.0,0.999900014499,0.999900014499,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inconclusive,superior,0
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,1,20.0,100.0,0.000201225280758,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,1,20.0,100.0,0.000201225280758,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,1,20.0,100.0,0.000201225280758,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,vancomycin,therapeutic,10,1,20.0,100.0,0.000201225280758,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,1,20.0,100.0,0.000201225280758,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,1,20.0,100.0,0.000201225280758,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,1,20.0,100.0,0.000201225280758,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,5.0,25.0,vancomycin,therapeutic,10,1,20.0,100.0,0.000201225280758,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,vancomycin,therapeutic,6,0,100.0,500.0,0.0723604618184,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,vancomycin,therapeutic,6,0,100.0,500.0,0.0723604618184,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,vancomycin,therapeutic,6,0,100.0,500.0,0.0723604618184,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,vancomycin,therapeutic,6,0,100.0,500.0,0.0723604618184,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inconclusive,superior,0
29439962,2018,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,vancomycin,therapeutic,6,0,100.0,500.0,0.999950001,0.999950001,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,vancomycin,therapeutic,6,0,100.0,500.0,0.999950001,0.999950001,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,vancomycin,therapeutic,6,0,100.0,500.0,0.999950001,0.999950001,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
29439962,2018,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,vancomycin,therapeutic,6,0,100.0,500.0,0.999950001,0.999950001,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inconclusive,superior,0
29439962,2018,sustained,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,3.0,15.0,vancomycin,therapeutic,6,0,100.0,500.0,0.0337882737941,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,sustained,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,3.0,15.0,vancomycin,therapeutic,6,0,100.0,500.0,0.0337882737941,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,sustained,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,3.0,15.0,vancomycin,therapeutic,6,0,100.0,500.0,0.0337882737941,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
29439962,2018,sustained,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,3.0,15.0,vancomycin,therapeutic,6,0,100.0,500.0,0.0337882737941,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.0437939533725,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.2,1.0,0.0437939533725,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,0.00397777557269,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,0.00397777557269,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,0.00397777557269,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,0.00397777557269,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,0.00397777557269,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,3,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,0.00397777557269,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,2.00271606436e-05,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,2.00271606436e-05,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,2.00271606436e-05,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,2.00271606436e-05,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,2.00271606436e-05,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,2.00271606436e-05,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.2,1.0,2.00271606436e-05,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.2,1.0,2.00271606436e-05,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.2,1.0,2.00271606436e-05,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.2,1.0,2.00271606436e-05,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.2,1.0,2.00271606436e-05,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.2,1.0,2.00271606436e-05,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,1.0,5.0,0.00397777557269,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,1.0,5.0,0.00397777557269,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,1.0,5.0,0.00397777557269,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,1.0,5.0,0.00397777557269,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,1.0,5.0,0.00397777557269,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,fidaxomicin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,1.0,5.0,0.00397777557269,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.0437939533725,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.0437939533725,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.0437939533725,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.0437939533725,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.0437939533725,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.0437939533725,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,4,5.0,25.0,0.999900014499,0.388331952824,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,4,5.0,25.0,0.999900014499,0.388331952824,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,4,5.0,25.0,0.999900014499,0.388331952824,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,4,5.0,25.0,0.999900014499,0.388331952824,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,4,5.0,25.0,0.999900014499,0.388331952824,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,4,5.0,25.0,0.999900014499,0.388331952824,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.0437939533725,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.0437939533725,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.0437939533725,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.0437939533725,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.0437939533725,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.0437939533725,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.999900014499,0.999900014499,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.0210952758787,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.0210952758787,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.0210952758787,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.0210952758787,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.0210952758787,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.0210952758787,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.0210952758787,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.0210952758787,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.0210952758787,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.0210952758787,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.0210952758787,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.0210952758787,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,9,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,9,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,9,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,9,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,9,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,fidaxomicin,therapeutic,10,9,5.0,25.0,0.999900014499,0.999900014499,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,1,0.3,1.5,0.9999999985,0.25903359665,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,1,0.3,1.5,0.9999999985,0.25903359665,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,1,0.3,1.5,0.9999999985,0.25903359665,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,1,0.3,1.5,0.9999999985,0.25903359665,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,1,0.3,1.5,0.9999999985,0.25903359665,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,30000.0,,spores,0.03,0.15,fidaxomicin,therapeutic,6,1,0.3,1.5,0.9999999985,0.25903359665,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.0936884497584,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.0936884497584,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.0936884497584,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.0936884497584,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.0936884497584,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.0936884497584,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,6,3,3.0,15.0,0.999950004,0.44295936323,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,6,3,3.0,15.0,0.999950004,0.44295936323,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,6,3,3.0,15.0,0.999950004,0.44295936323,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,6,3,3.0,15.0,0.999950004,0.44295936323,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,6,3,3.0,15.0,0.999950004,0.44295936323,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,2.0,10.0,fidaxomicin,therapeutic,6,3,3.0,15.0,0.999950004,0.44295936323,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,fidaxomicin,therapeutic,6,3,3.0,15.0,1.0,0.0485404000014,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,fidaxomicin,therapeutic,6,3,3.0,15.0,1.0,0.0485404000014,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,fidaxomicin,therapeutic,6,3,3.0,15.0,1.0,0.0485404000014,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,fidaxomicin,therapeutic,6,3,3.0,15.0,1.0,0.0485404000014,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,fidaxomicin,therapeutic,6,3,3.0,15.0,1.0,0.0485404000014,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,1.0,1.0,fidaxomicin,therapeutic,6,3,3.0,15.0,1.0,0.0485404000014,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,sustained,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.0485404000014,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,sustained,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.0485404000014,1.0,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,sustained,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.0485404000014,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,sustained,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.0485404000014,1.0,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,fidaxomicin,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,sustained,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.0485404000014,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,superior,inconclusive,0
29439962,2018,sustained,6,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,fidaxomicin,,,40000.0,,spores,3.0,15.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.0485404000014,1.0,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,fidaxomicin,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inconclusive,inferior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.04,0.2,0.999900014499,0.999900014499,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inconclusive,inferior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inconclusive,inferior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inconclusive,inferior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.04,0.2,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inconclusive,inferior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,0,0.2,1.0,0.999900014499,0.999900014499,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inconclusive,inferior,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,3,1.0,5.0,1.0,0.0437939533725,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
33495229,2021,sustained,10,0,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,0.2,1.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,2.00271606436e-05,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.00638961791984,1.0,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.00638961791984,1.0,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.00638961791984,1.0,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,superior,inferior,0
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.04,0.2,0.00638961791984,1.0,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,superior,inferior,0
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.2,1.0,0.00638961791984,1.0,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.2,1.0,0.00638961791984,1.0,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.2,1.0,0.00638961791984,1.0,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,superior,inferior,0
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,0,0.2,1.0,0.00638961791984,1.0,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,superior,inferior,0
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,1.0,5.0,0.261737155132,0.999900014499,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,1.0,5.0,0.261737155132,0.999900014499,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,1.0,5.0,0.261737155132,0.999900014499,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inconclusive,inferior,0
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,3,1.0,5.0,0.261737155132,0.999900014499,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inconclusive,inferior,0
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,0.0311548075887,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,0.0311548075887,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,0.0311548075887,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
33495229,2021,sustained,10,5,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,1.0,5.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,0.0311548075887,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,2.00271606436e-05,1.0,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,2.00271606436e-05,1.0,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,2.00271606436e-05,1.0,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,superior,inferior,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.04,0.2,2.00271606436e-05,1.0,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,superior,inferior,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.2,1.0,2.00271606436e-05,1.0,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.2,1.0,2.00271606436e-05,1.0,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.2,1.0,2.00271606436e-05,1.0,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,superior,inferior,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,0,0.2,1.0,2.00271606436e-05,1.0,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,superior,inferior,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,1.0,5.0,0.00397777557269,1.0,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,1.0,5.0,0.00397777557269,1.0,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,superior,inconclusive,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,1.0,5.0,0.00397777557269,1.0,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,superior,inferior,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,3,1.0,5.0,0.00397777557269,1.0,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,superior,inferior,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,9,5.0,25.0,0.999900014499,0.999900014499,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,9,5.0,25.0,0.999900014499,0.999900014499,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,9,5.0,25.0,0.999900014499,0.999900014499,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inconclusive,inferior,0
33495229,2021,sustained,10,9,positive,SPF,Golden Syrian,M,hamster,challenge+clindamycin,survival,therapeutic,87.0,VPI 10463,vancomycin,39.0,,1000000.0,CFU,,5.0,25.0,fidaxomicin,therapeutic,10,9,5.0,25.0,0.999900014499,0.999900014499,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inconclusive,inferior,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,3,2.0,10.0,1.0,0.0437939533725,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.999900014499,0.999900014499,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.999900014499,0.999900014499,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.999900014499,0.999900014499,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inconclusive,inferior,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.999900014499,0.999900014499,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inconclusive,inferior,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,4,5.0,25.0,1.0,0.0210952758787,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.999900014499,0.999900014499,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.999900014499,0.999900014499,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.999900014499,0.999900014499,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inconclusive,inferior,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.999900014499,0.999900014499,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inconclusive,inferior,0
25652749,2015,sustained,10,1,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,9,2.0,10.0,1.0,0.000201225280758,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,1,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,9,2.0,10.0,1.0,0.000201225280758,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,1,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,9,2.0,10.0,1.0,0.000201225280758,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
25652749,2015,sustained,10,1,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,9,2.0,10.0,1.0,0.000201225280758,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
25652749,2015,sustained,10,1,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,0.000201225280758,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,1,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,0.000201225280758,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,1,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,0.000201225280758,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
25652749,2015,sustained,10,1,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,fidaxomicin,therapeutic,10,9,5.0,25.0,1.0,0.000201225280758,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,40000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,5,2,2.0,10.0,1.0,0.0723604618184,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,40000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,5,2,2.0,10.0,1.0,0.0723604618184,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,40000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,5,2,2.0,10.0,1.0,0.0723604618184,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inconclusive,inferior,0
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,40000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,5,2,2.0,10.0,1.0,0.0723604618184,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inconclusive,inferior,0
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,40000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.999950001,0.999950001,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,40000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.999950001,0.999950001,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,40000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.999950001,0.999950001,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inconclusive,inferior,0
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,40000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,5,0,1.0,1.0,0.999950001,0.999950001,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inconclusive,inferior,0
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,40000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,3,3.0,15.0,1.0,0.0337882737941,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,fidaxomicin,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,40000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,3,3.0,15.0,1.0,0.0337882737941,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,fidaxomicin,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,40000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,3,3.0,15.0,1.0,0.0337882737941,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,fidaxomicin,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
29439962,2018,sustained,6,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,2009155,vancomycin,,,40000.0,,spores,100.0,500.0,fidaxomicin,therapeutic,6,3,3.0,15.0,1.0,0.0337882737941,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,fidaxomicin,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
27527088,2016,sustained,10,2,positive,SPF,C57BL/6,,mouse,cefoperazone + clindamycin + challenge,cumulative mortality,therapeutic,87.0,VPI 10463,vancomycin,56.0,,1000000.0,CFU,vegetative,20.0,100.0,actoxumab/bezlotoxumab,therapeutic,10,9,50.0,100.0,1.0,0.00128841400146,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,27.6,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,antibody,actoxumab/bezlotoxumab,383,323,20.0,20.0,1.0,2.72855253199e-05,intervention.Variation,comparator.Variation,inferior,inferior,1
27527088,2016,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,680.0,CFU,spores,20.0,100.0,actoxumab/bezlotoxumab,therapeutic,10,4,50.0,200.0,1.0,0.0210952758787,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,27.6,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,antibody,actoxumab/bezlotoxumab,383,323,20.0,20.0,1.0,2.72855253199e-05,intervention.Variation,comparator.Variation,inferior,inferior,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,24,20.0,100.0,0.999999947224,0.312404213167,NCT01085591-1,acute,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,61,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,antibiotic,vancomycin,66,59,500.0,5000.0,0.29413098603,0.999340649771,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,24,20.0,100.0,0.999999947224,0.312404213167,NCT01085591-3,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,58,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,antibiotic,vancomycin,66,59,500.0,5000.0,0.999340656221,0.345333712741,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,24,20.0,100.0,0.999999947224,0.312404213167,NCT01597505-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,79.0 (73.9 to 83.2),Non-Inferiority,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,229,antibiotic,vancomycin,280,234,500.0,5000.0,0.999999995997,0.101122945492,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,24,20.0,100.0,0.999999947224,0.312404213167,NCT01598311-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,83.4 (78.7 to 87.2),Non-Inferiority,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,237,antibiotic,vancomycin,292,239,500.0,5000.0,0.38557995153,0.997162329539,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,24,4.0,20.0,0.999999947224,0.312404213167,NCT01085591-1,acute,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,61,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,antibiotic,vancomycin,66,59,500.0,5000.0,0.29413098603,0.999340649771,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,24,4.0,20.0,0.999999947224,0.312404213167,NCT01085591-3,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,58,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,antibiotic,vancomycin,66,59,500.0,5000.0,0.999340656221,0.345333712741,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,24,4.0,20.0,0.999999947224,0.312404213167,NCT01597505-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,79.0 (73.9 to 83.2),Non-Inferiority,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,229,antibiotic,vancomycin,280,234,500.0,5000.0,0.999999995997,0.101122945492,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,24,4.0,20.0,0.999999947224,0.312404213167,NCT01598311-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,83.4 (78.7 to 87.2),Non-Inferiority,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,237,antibiotic,vancomycin,292,239,500.0,5000.0,0.38557995153,0.997162329539,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,16,16,50.0,250.0,0.999999947219,0.392937882059,NCT01085591-1,acute,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,61,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,antibiotic,vancomycin,66,59,500.0,5000.0,0.29413098603,0.999340649771,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,16,16,50.0,250.0,0.999999947219,0.392937882059,NCT01085591-3,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,58,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,antibiotic,vancomycin,66,59,500.0,5000.0,0.999340656221,0.345333712741,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,16,16,50.0,250.0,0.999999947219,0.392937882059,NCT01597505-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,79.0 (73.9 to 83.2),Non-Inferiority,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,229,antibiotic,vancomycin,280,234,500.0,5000.0,0.999999995997,0.101122945492,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,16,16,50.0,250.0,0.999999947219,0.392937882059,NCT01598311-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,83.4 (78.7 to 87.2),Non-Inferiority,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,237,antibiotic,vancomycin,292,239,500.0,5000.0,0.38557995153,0.997162329539,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,32,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,24,20.0,100.0,0.99976002761,0.99976002761,NCT01085591-1,acute,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,61,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,antibiotic,vancomycin,66,59,500.0,5000.0,0.29413098603,0.999340649771,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,32,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,24,20.0,100.0,0.99976002761,0.99976002761,NCT01085591-3,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,58,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,antibiotic,vancomycin,66,59,500.0,5000.0,0.999340656221,0.345333712741,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,32,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,24,20.0,100.0,0.99976002761,0.99976002761,NCT01597505-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,79.0 (73.9 to 83.2),Non-Inferiority,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,229,antibiotic,vancomycin,280,234,500.0,5000.0,0.999999995997,0.101122945492,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,32,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,24,20.0,100.0,0.99976002761,0.99976002761,NCT01598311-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,83.4 (78.7 to 87.2),Non-Inferiority,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,237,antibiotic,vancomycin,292,239,500.0,5000.0,0.38557995153,0.997162329539,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,32,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,24,4.0,20.0,0.99976002761,0.99976002761,NCT01085591-1,acute,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,61,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,antibiotic,vancomycin,66,59,500.0,5000.0,0.29413098603,0.999340649771,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,32,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,24,4.0,20.0,0.99976002761,0.99976002761,NCT01085591-3,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,58,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,antibiotic,vancomycin,66,59,500.0,5000.0,0.999340656221,0.345333712741,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,32,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,24,4.0,20.0,0.99976002761,0.99976002761,NCT01597505-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,79.0 (73.9 to 83.2),Non-Inferiority,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,229,antibiotic,vancomycin,280,234,500.0,5000.0,0.999999995997,0.101122945492,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,32,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,24,4.0,20.0,0.99976002761,0.99976002761,NCT01598311-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,83.4 (78.7 to 87.2),Non-Inferiority,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,237,antibiotic,vancomycin,292,239,500.0,5000.0,0.38557995153,0.997162329539,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,32,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,16,16,50.0,250.0,0.999840012007,0.999840012007,NCT01085591-1,acute,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,61,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,antibiotic,vancomycin,66,59,500.0,5000.0,0.29413098603,0.999340649771,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,32,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,16,16,50.0,250.0,0.999840012007,0.999840012007,NCT01085591-3,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,58,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,antibiotic,vancomycin,66,59,500.0,5000.0,0.999340656221,0.345333712741,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,32,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,16,16,50.0,250.0,0.999840012007,0.999840012007,NCT01597505-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,79.0 (73.9 to 83.2),Non-Inferiority,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,229,antibiotic,vancomycin,280,234,500.0,5000.0,0.999999995997,0.101122945492,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,32,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,16,16,50.0,250.0,0.999840012007,0.999840012007,NCT01598311-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,83.4 (78.7 to 87.2),Non-Inferiority,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,237,antibiotic,vancomycin,292,239,500.0,5000.0,0.38557995153,0.997162329539,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,24,20.0,100.0,0.999840012004,0.999840012004,NCT01085591-1,acute,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,61,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,antibiotic,vancomycin,66,59,500.0,5000.0,0.29413098603,0.999340649771,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,24,20.0,100.0,0.999840012004,0.999840012004,NCT01085591-3,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,58,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,antibiotic,vancomycin,66,59,500.0,5000.0,0.999340656221,0.345333712741,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,24,20.0,100.0,0.999840012004,0.999840012004,NCT01597505-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,79.0 (73.9 to 83.2),Non-Inferiority,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,229,antibiotic,vancomycin,280,234,500.0,5000.0,0.999999995997,0.101122945492,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,24,20.0,100.0,0.999840012004,0.999840012004,NCT01598311-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,83.4 (78.7 to 87.2),Non-Inferiority,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,237,antibiotic,vancomycin,292,239,500.0,5000.0,0.38557995153,0.997162329539,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,24,4.0,20.0,0.999840012004,0.999840012004,NCT01085591-1,acute,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,61,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,antibiotic,vancomycin,66,59,500.0,5000.0,0.29413098603,0.999340649771,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,24,4.0,20.0,0.999840012004,0.999840012004,NCT01085591-3,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,58,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,antibiotic,vancomycin,66,59,500.0,5000.0,0.999340656221,0.345333712741,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,24,4.0,20.0,0.999840012004,0.999840012004,NCT01597505-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,79.0 (73.9 to 83.2),Non-Inferiority,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,229,antibiotic,vancomycin,280,234,500.0,5000.0,0.999999995997,0.101122945492,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,24,4.0,20.0,0.999840012004,0.999840012004,NCT01598311-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,83.4 (78.7 to 87.2),Non-Inferiority,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,237,antibiotic,vancomycin,292,239,500.0,5000.0,0.38557995153,0.997162329539,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,16,16,50.0,250.0,0.999840037594,0.999840037594,NCT01085591-1,acute,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,61,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,antibiotic,vancomycin,66,59,500.0,5000.0,0.29413098603,0.999340649771,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,16,16,50.0,250.0,0.999840037594,0.999840037594,NCT01085591-3,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,58,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,antibiotic,vancomycin,66,59,500.0,5000.0,0.999340656221,0.345333712741,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,16,16,50.0,250.0,0.999840037594,0.999840037594,NCT01597505-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,79.0 (73.9 to 83.2),Non-Inferiority,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,229,antibiotic,vancomycin,280,234,500.0,5000.0,0.999999995997,0.101122945492,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,16,16,50.0,250.0,0.999840037594,0.999840037594,NCT01598311-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,83.4 (78.7 to 87.2),Non-Inferiority,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,237,antibiotic,vancomycin,292,239,500.0,5000.0,0.38557995153,0.997162329539,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,32,32,4.0,20.0,0.999999947228,0.269988451083,NCT01085591-1,acute,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,61,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,antibiotic,"CB-183,315",67,58,500.0,5000.0,0.149871813117,0.999999785735,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,32,32,4.0,20.0,0.999999947228,0.269988451083,NCT01085591-3,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,58,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,antibiotic,"CB-183,315",66,61,250.0,2500.0,0.999999785735,0.149871813117,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999999947219,0.392937882059,NCT01085591-1,acute,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,61,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,antibiotic,"CB-183,315",67,58,500.0,5000.0,0.149871813117,0.999999785735,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,33,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999999947219,0.392937882059,NCT01085591-3,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,58,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,antibiotic,"CB-183,315",66,61,250.0,2500.0,0.999999785735,0.149871813117,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,32,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999840012007,0.999840012007,NCT01085591-1,acute,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,61,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,antibiotic,"CB-183,315",67,58,500.0,5000.0,0.149871813117,0.999999785735,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,32,32,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999840012007,0.999840012007,NCT01085591-3,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,58,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,antibiotic,"CB-183,315",66,61,250.0,2500.0,0.999999785735,0.149871813117,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,33,32,20.0,100.0,0.312404213167,0.999999947224,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",66,61,250.0,2500.0,0.999340649771,0.29413098603,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,33,32,20.0,100.0,0.312404213167,0.999999947224,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",67,58,500.0,5000.0,0.345333712741,0.999340656221,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,33,32,20.0,100.0,0.312404213167,0.999999947224,NCT01597505-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,83.6 (78.8 to 87.4),,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,antibiotic,"CB-183,315",290,229,500.0,5000.0,0.101122945492,0.999999995997,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,33,32,20.0,100.0,0.312404213167,0.999999947224,NCT01598311-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,82.1 (77.2 to 85.9),,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,antibiotic,"CB-183,315",285,237,500.0,5000.0,0.997162329539,0.38557995153,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,32,32,4.0,20.0,0.99976002761,0.99976002761,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",66,61,250.0,2500.0,0.999340649771,0.29413098603,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,32,32,4.0,20.0,0.99976002761,0.99976002761,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",67,58,500.0,5000.0,0.345333712741,0.999340656221,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,32,32,4.0,20.0,0.99976002761,0.99976002761,NCT01597505-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,83.6 (78.8 to 87.4),,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,antibiotic,"CB-183,315",290,229,500.0,5000.0,0.101122945492,0.999999995997,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,32,32,4.0,20.0,0.99976002761,0.99976002761,NCT01598311-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,82.1 (77.2 to 85.9),,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,antibiotic,"CB-183,315",285,237,500.0,5000.0,0.997162329539,0.38557995153,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999840012004,0.999840012004,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",66,61,250.0,2500.0,0.999340649771,0.29413098603,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999840012004,0.999840012004,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",67,58,500.0,5000.0,0.345333712741,0.999340656221,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999840012004,0.999840012004,NCT01597505-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,83.6 (78.8 to 87.4),,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,antibiotic,"CB-183,315",290,229,500.0,5000.0,0.101122945492,0.999999995997,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999840012004,0.999840012004,NCT01598311-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,82.1 (77.2 to 85.9),,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,antibiotic,"CB-183,315",285,237,500.0,5000.0,0.997162329539,0.38557995153,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,33,32,20.0,100.0,0.312404213167,0.999999947224,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",66,61,250.0,2500.0,0.999340649771,0.29413098603,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,33,32,20.0,100.0,0.312404213167,0.999999947224,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",67,58,500.0,5000.0,0.345333712741,0.999340656221,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,33,32,20.0,100.0,0.312404213167,0.999999947224,NCT01597505-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,83.6 (78.8 to 87.4),,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,antibiotic,"CB-183,315",290,229,500.0,5000.0,0.101122945492,0.999999995997,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,33,32,20.0,100.0,0.312404213167,0.999999947224,NCT01598311-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,82.1 (77.2 to 85.9),,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,antibiotic,"CB-183,315",285,237,500.0,5000.0,0.997162329539,0.38557995153,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,32,32,4.0,20.0,0.99976002761,0.99976002761,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",66,61,250.0,2500.0,0.999340649771,0.29413098603,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,32,32,4.0,20.0,0.99976002761,0.99976002761,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",67,58,500.0,5000.0,0.345333712741,0.999340656221,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,32,32,4.0,20.0,0.99976002761,0.99976002761,NCT01597505-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,83.6 (78.8 to 87.4),,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,antibiotic,"CB-183,315",290,229,500.0,5000.0,0.101122945492,0.999999995997,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,32,32,4.0,20.0,0.99976002761,0.99976002761,NCT01598311-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,82.1 (77.2 to 85.9),,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,antibiotic,"CB-183,315",285,237,500.0,5000.0,0.997162329539,0.38557995153,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999840012004,0.999840012004,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",66,61,250.0,2500.0,0.999340649771,0.29413098603,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999840012004,0.999840012004,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",67,58,500.0,5000.0,0.345333712741,0.999340656221,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999840012004,0.999840012004,NCT01597505-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,83.6 (78.8 to 87.4),,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,antibiotic,"CB-183,315",290,229,500.0,5000.0,0.101122945492,0.999999995997,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,24,24,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999840012004,0.999840012004,NCT01598311-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,82.1 (77.2 to 85.9),,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,antibiotic,"CB-183,315",285,237,500.0,5000.0,0.997162329539,0.38557995153,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,33,32,20.0,100.0,0.392937882059,0.999999947219,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",66,61,250.0,2500.0,0.999340649771,0.29413098603,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,33,32,20.0,100.0,0.392937882059,0.999999947219,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",67,58,500.0,5000.0,0.345333712741,0.999340656221,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,33,32,20.0,100.0,0.392937882059,0.999999947219,NCT01597505-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,83.6 (78.8 to 87.4),,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,antibiotic,"CB-183,315",290,229,500.0,5000.0,0.101122945492,0.999999995997,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,33,32,20.0,100.0,0.392937882059,0.999999947219,NCT01598311-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,82.1 (77.2 to 85.9),,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,antibiotic,"CB-183,315",285,237,500.0,5000.0,0.997162329539,0.38557995153,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,32,32,4.0,20.0,0.999840012007,0.999840012007,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",66,61,250.0,2500.0,0.999340649771,0.29413098603,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,32,32,4.0,20.0,0.999840012007,0.999840012007,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",67,58,500.0,5000.0,0.345333712741,0.999340656221,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,32,32,4.0,20.0,0.999840012007,0.999840012007,NCT01597505-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,83.6 (78.8 to 87.4),,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,antibiotic,"CB-183,315",290,229,500.0,5000.0,0.101122945492,0.999999995997,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,32,32,4.0,20.0,0.999840012007,0.999840012007,NCT01598311-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,82.1 (77.2 to 85.9),,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,antibiotic,"CB-183,315",285,237,500.0,5000.0,0.997162329539,0.38557995153,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999840037594,0.999840037594,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",66,61,250.0,2500.0,0.999340649771,0.29413098603,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999840037594,0.999840037594,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,"CB-183,315",67,58,500.0,5000.0,0.345333712741,0.999340656221,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999840037594,0.999840037594,NCT01597505-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,83.6 (78.8 to 87.4),,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,antibiotic,"CB-183,315",290,229,500.0,5000.0,0.101122945492,0.999999995997,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,acute,16,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,16,16,50.0,250.0,0.999840037594,0.999840037594,NCT01598311-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,82.1 (77.2 to 85.9),,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,antibiotic,"CB-183,315",285,237,500.0,5000.0,0.997162329539,0.38557995153,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,21,20.0,100.0,0.999999947224,0.205757074756,NCT01085591-7,sustained,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,antibiotic,vancomycin,59,38,500.0,5000.0,0.271120163143,0.999410530755,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,21,20.0,100.0,0.999999947224,0.205757074756,NCT01085591-10,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,antibiotic,vancomycin,59,38,500.0,5000.0,0.013104683434,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,21,20.0,100.0,0.999999947224,0.205757074756,NCT01597505-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,60.6 (55.0 to 66.0),not superior,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,175,antibiotic,vancomycin,280,171,500.0,5000.0,0.997211988086,0.455437437134,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,21,20.0,100.0,0.999999947224,0.205757074756,NCT01598311-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,63.3 (57.7 to 68.7),not superior,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,180,antibiotic,vancomycin,292,172,500.0,5000.0,0.152619871147,0.999995972405,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,13,4.0,20.0,0.0491394617522,1.0,NCT01085591-7,sustained,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,antibiotic,vancomycin,59,38,500.0,5000.0,0.271120163143,0.999410530755,intervention.Specific,comparator.Specific,superior,inconclusive,0
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,13,4.0,20.0,0.0491394617522,1.0,NCT01085591-10,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,antibiotic,vancomycin,59,38,500.0,5000.0,0.013104683434,1.0,intervention.Specific,comparator.Specific,superior,superior,1
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,13,4.0,20.0,0.0491394617522,1.0,NCT01597505-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,60.6 (55.0 to 66.0),not superior,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,175,antibiotic,vancomycin,280,171,500.0,5000.0,0.997211988086,0.455437437134,intervention.Specific,comparator.Specific,superior,inconclusive,0
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,24,13,4.0,20.0,0.0491394617522,1.0,NCT01598311-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,63.3 (57.7 to 68.7),not superior,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,180,antibiotic,vancomycin,292,172,500.0,5000.0,0.152619871147,0.999995972405,intervention.Specific,comparator.Specific,superior,inconclusive,0
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,16,11,50.0,250.0,0.40038253395,0.999840012008,NCT01085591-7,sustained,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,antibiotic,vancomycin,59,38,500.0,5000.0,0.271120163143,0.999410530755,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,16,11,50.0,250.0,0.40038253395,0.999840012008,NCT01085591-10,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,antibiotic,vancomycin,59,38,500.0,5000.0,0.013104683434,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,16,11,50.0,250.0,0.40038253395,0.999840012008,NCT01597505-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,60.6 (55.0 to 66.0),not superior,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,175,antibiotic,vancomycin,280,171,500.0,5000.0,0.997211988086,0.455437437134,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,vancomycin,therapeutic,16,11,50.0,250.0,0.40038253395,0.999840012008,NCT01598311-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,63.3 (57.7 to 68.7),not superior,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,180,antibiotic,vancomycin,292,172,500.0,5000.0,0.152619871147,0.999995972405,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,21,20.0,100.0,1.0,0.00178741846354,NCT01085591-7,sustained,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,antibiotic,vancomycin,59,38,500.0,5000.0,0.271120163143,0.999410530755,intervention.Specific,comparator.Specific,inferior,inconclusive,0
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,21,20.0,100.0,1.0,0.00178741846354,NCT01085591-10,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,antibiotic,vancomycin,59,38,500.0,5000.0,0.013104683434,1.0,intervention.Specific,comparator.Specific,inferior,superior,0
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,21,20.0,100.0,1.0,0.00178741846354,NCT01597505-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,60.6 (55.0 to 66.0),not superior,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,175,antibiotic,vancomycin,280,171,500.0,5000.0,0.997211988086,0.455437437134,intervention.Specific,comparator.Specific,inferior,inconclusive,0
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,21,20.0,100.0,1.0,0.00178741846354,NCT01598311-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,63.3 (57.7 to 68.7),not superior,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,180,antibiotic,vancomycin,292,172,500.0,5000.0,0.152619871147,0.999995972405,intervention.Specific,comparator.Specific,inferior,inconclusive,0
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,13,4.0,20.0,0.999760104368,0.432779727183,NCT01085591-7,sustained,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,antibiotic,vancomycin,59,38,500.0,5000.0,0.271120163143,0.999410530755,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,13,4.0,20.0,0.999760104368,0.432779727183,NCT01085591-10,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,antibiotic,vancomycin,59,38,500.0,5000.0,0.013104683434,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,13,4.0,20.0,0.999760104368,0.432779727183,NCT01597505-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,60.6 (55.0 to 66.0),not superior,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,175,antibiotic,vancomycin,280,171,500.0,5000.0,0.997211988086,0.455437437134,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,24,13,4.0,20.0,0.999760104368,0.432779727183,NCT01598311-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,63.3 (57.7 to 68.7),not superior,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,180,antibiotic,vancomycin,292,172,500.0,5000.0,0.152619871147,0.999995972405,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,16,11,50.0,250.0,0.999999999995,0.183936001327,NCT01085591-7,sustained,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,antibiotic,vancomycin,59,38,500.0,5000.0,0.271120163143,0.999410530755,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,16,11,50.0,250.0,0.999999999995,0.183936001327,NCT01085591-10,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,antibiotic,vancomycin,59,38,500.0,5000.0,0.013104683434,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,16,11,50.0,250.0,0.999999999995,0.183936001327,NCT01597505-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,60.6 (55.0 to 66.0),not superior,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,175,antibiotic,vancomycin,280,171,500.0,5000.0,0.997211988086,0.455437437134,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,vancomycin,therapeutic,16,11,50.0,250.0,0.999999999995,0.183936001327,NCT01598311-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,63.3 (57.7 to 68.7),not superior,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,180,antibiotic,vancomycin,292,172,500.0,5000.0,0.152619871147,0.999995972405,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,21,20.0,100.0,0.999840050389,0.355781657473,NCT01085591-7,sustained,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,antibiotic,vancomycin,59,38,500.0,5000.0,0.271120163143,0.999410530755,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,21,20.0,100.0,0.999840050389,0.355781657473,NCT01085591-10,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,antibiotic,vancomycin,59,38,500.0,5000.0,0.013104683434,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
22802252,2012,sustained,16,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,21,20.0,100.0,0.999840050389,0.355781657473,NCT01597505-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,60.6 (55.0 to 66.0),not superior,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,175,antibiotic,vancomycin,280,171,500.0,5000.0,0.997211988086,0.455437437134,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,21,20.0,100.0,0.999840050389,0.355781657473,NCT01598311-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,63.3 (57.7 to 68.7),not superior,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,180,antibiotic,vancomycin,292,172,500.0,5000.0,0.152619871147,0.999995972405,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,13,4.0,20.0,0.0624000138625,1.0,NCT01085591-7,sustained,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,antibiotic,vancomycin,59,38,500.0,5000.0,0.271120163143,0.999410530755,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,13,4.0,20.0,0.0624000138625,1.0,NCT01085591-10,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,antibiotic,vancomycin,59,38,500.0,5000.0,0.013104683434,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
22802252,2012,sustained,16,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,13,4.0,20.0,0.0624000138625,1.0,NCT01597505-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,60.6 (55.0 to 66.0),not superior,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,175,antibiotic,vancomycin,280,171,500.0,5000.0,0.997211988086,0.455437437134,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,24,13,4.0,20.0,0.0624000138625,1.0,NCT01598311-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,63.3 (57.7 to 68.7),not superior,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,180,antibiotic,vancomycin,292,172,500.0,5000.0,0.152619871147,0.999995972405,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,16,11,50.0,250.0,0.263434612261,0.999840037596,NCT01085591-7,sustained,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,antibiotic,vancomycin,59,38,500.0,5000.0,0.271120163143,0.999410530755,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,16,11,50.0,250.0,0.263434612261,0.999840037596,NCT01085591-10,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,antibiotic,vancomycin,59,38,500.0,5000.0,0.013104683434,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
22802252,2012,sustained,16,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,16,11,50.0,250.0,0.263434612261,0.999840037596,NCT01597505-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,60.6 (55.0 to 66.0),not superior,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,175,antibiotic,vancomycin,280,171,500.0,5000.0,0.997211988086,0.455437437134,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,vancomycin,therapeutic,16,11,50.0,250.0,0.263434612261,0.999840037596,NCT01598311-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,63.3 (57.7 to 68.7),not superior,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,180,antibiotic,vancomycin,292,172,500.0,5000.0,0.152619871147,0.999995972405,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.0173382151998,1.0,NCT01085591-7,sustained,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,antibiotic,"CB-183,315",58,48,500.0,5000.0,0.999999834862,0.11230700552,intervention.Specific,comparator.Specific,superior,inconclusive,0
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.0173382151998,1.0,NCT01085591-10,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,antibiotic,"CB-183,315",61,44,250.0,2500.0,0.11230700552,0.999999834862,intervention.Specific,comparator.Specific,superior,inconclusive,0
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,16,13,50.0,250.0,0.999840012008,0.400482788657,NCT01085591-7,sustained,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,antibiotic,"CB-183,315",58,48,500.0,5000.0,0.999999834862,0.11230700552,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,33,25,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,16,13,50.0,250.0,0.999840012008,0.400482788657,NCT01085591-10,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,antibiotic,"CB-183,315",61,44,250.0,2500.0,0.11230700552,0.999999834862,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,33,25,20.0,100.0,1.0,0.0173382151998,NCT01085591-7,sustained,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,antibiotic,"CB-183,315",58,48,500.0,5000.0,0.999999834862,0.11230700552,intervention.Specific,comparator.Specific,inferior,inconclusive,0
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,33,25,20.0,100.0,1.0,0.0173382151998,NCT01085591-10,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,antibiotic,"CB-183,315",61,44,250.0,2500.0,0.11230700552,0.999999834862,intervention.Specific,comparator.Specific,inferior,inconclusive,0
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,16,13,50.0,250.0,1.0,0.0225270484904,NCT01085591-7,sustained,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,antibiotic,"CB-183,315",58,48,500.0,5000.0,0.999999834862,0.11230700552,intervention.Specific,comparator.Specific,inferior,inconclusive,0
22802252,2012,sustained,32,16,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,16,13,50.0,250.0,1.0,0.0225270484904,NCT01085591-10,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,antibiotic,"CB-183,315",61,44,250.0,2500.0,0.11230700552,0.999999834862,intervention.Specific,comparator.Specific,inferior,inconclusive,0
22802252,2012,sustained,16,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.0225270484904,1.0,NCT01085591-7,sustained,250.0,2500.0,125,mg,BID,10.0,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,antibiotic,"CB-183,315",58,48,500.0,5000.0,0.999999834862,0.11230700552,intervention.Specific,comparator.Specific,superior,inconclusive,0
22802252,2012,sustained,16,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,"CB-183,315",,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.0225270484904,1.0,NCT01085591-10,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,antibiotic,"CB-183,315",61,44,250.0,2500.0,0.11230700552,0.999999834862,intervention.Specific,comparator.Specific,superior,inconclusive,0
22802252,2012,sustained,24,21,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,33,25,20.0,100.0,0.205757074756,0.999999947224,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",61,44,250.0,2500.0,0.999410530755,0.271120163143,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,24,21,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,33,25,20.0,100.0,0.205757074756,0.999999947224,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",58,48,500.0,5000.0,1.0,0.013104683434,intervention.Specific,comparator.Specific,inconclusive,inferior,0
22802252,2012,sustained,24,21,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,33,25,20.0,100.0,0.205757074756,0.999999947224,NCT01597505-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,61.4 (55.9 to 66.8)  ,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,antibiotic,"CB-183,315",290,175,500.0,5000.0,0.455437437134,0.997211988086,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,24,21,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,33,25,20.0,100.0,0.205757074756,0.999999947224,NCT01598311-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,59.0 (53.4 to 64.5),,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,antibiotic,"CB-183,315",285,180,500.0,5000.0,0.999995972405,0.152619871147,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,24,21,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.00178741846354,1.0,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",61,44,250.0,2500.0,0.999410530755,0.271120163143,intervention.Specific,comparator.Specific,superior,inconclusive,0
22802252,2012,sustained,24,21,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.00178741846354,1.0,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",58,48,500.0,5000.0,1.0,0.013104683434,intervention.Specific,comparator.Specific,superior,inferior,0
22802252,2012,sustained,24,21,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.00178741846354,1.0,NCT01597505-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,61.4 (55.9 to 66.8)  ,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,antibiotic,"CB-183,315",290,175,500.0,5000.0,0.455437437134,0.997211988086,intervention.Specific,comparator.Specific,superior,inconclusive,0
22802252,2012,sustained,24,21,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.00178741846354,1.0,NCT01598311-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,59.0 (53.4 to 64.5),,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,antibiotic,"CB-183,315",285,180,500.0,5000.0,0.999995972405,0.152619871147,intervention.Specific,comparator.Specific,superior,inconclusive,0
22802252,2012,sustained,24,21,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,16,13,50.0,250.0,0.355781657473,0.999840050389,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",61,44,250.0,2500.0,0.999410530755,0.271120163143,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,24,21,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,16,13,50.0,250.0,0.355781657473,0.999840050389,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",58,48,500.0,5000.0,1.0,0.013104683434,intervention.Specific,comparator.Specific,inconclusive,inferior,0
22802252,2012,sustained,24,21,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,16,13,50.0,250.0,0.355781657473,0.999840050389,NCT01597505-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,61.4 (55.9 to 66.8)  ,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,antibiotic,"CB-183,315",290,175,500.0,5000.0,0.455437437134,0.997211988086,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,24,21,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,20.0,100.0,"CB-183,315",therapeutic,16,13,50.0,250.0,0.355781657473,0.999840050389,NCT01598311-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,59.0 (53.4 to 64.5),,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,antibiotic,"CB-183,315",285,180,500.0,5000.0,0.999995972405,0.152619871147,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,24,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,33,25,20.0,100.0,1.0,0.0491394617522,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",61,44,250.0,2500.0,0.999410530755,0.271120163143,intervention.Specific,comparator.Specific,inferior,inconclusive,0
22802252,2012,sustained,24,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,33,25,20.0,100.0,1.0,0.0491394617522,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",58,48,500.0,5000.0,1.0,0.013104683434,intervention.Specific,comparator.Specific,inferior,inferior,1
22802252,2012,sustained,24,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,33,25,20.0,100.0,1.0,0.0491394617522,NCT01597505-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,61.4 (55.9 to 66.8)  ,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,antibiotic,"CB-183,315",290,175,500.0,5000.0,0.455437437134,0.997211988086,intervention.Specific,comparator.Specific,inferior,inconclusive,0
22802252,2012,sustained,24,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,33,25,20.0,100.0,1.0,0.0491394617522,NCT01598311-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,59.0 (53.4 to 64.5),,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,antibiotic,"CB-183,315",285,180,500.0,5000.0,0.999995972405,0.152619871147,intervention.Specific,comparator.Specific,inferior,inconclusive,0
22802252,2012,sustained,24,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.432779727183,0.999760104368,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",61,44,250.0,2500.0,0.999410530755,0.271120163143,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,24,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.432779727183,0.999760104368,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",58,48,500.0,5000.0,1.0,0.013104683434,intervention.Specific,comparator.Specific,inconclusive,inferior,0
22802252,2012,sustained,24,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.432779727183,0.999760104368,NCT01597505-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,61.4 (55.9 to 66.8)  ,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,antibiotic,"CB-183,315",290,175,500.0,5000.0,0.455437437134,0.997211988086,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,24,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.432779727183,0.999760104368,NCT01598311-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,59.0 (53.4 to 64.5),,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,antibiotic,"CB-183,315",285,180,500.0,5000.0,0.999995972405,0.152619871147,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,24,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,16,13,50.0,250.0,1.0,0.0624000138625,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",61,44,250.0,2500.0,0.999410530755,0.271120163143,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,24,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,16,13,50.0,250.0,1.0,0.0624000138625,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",58,48,500.0,5000.0,1.0,0.013104683434,intervention.Specific,comparator.Specific,inconclusive,inferior,0
22802252,2012,sustained,24,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,16,13,50.0,250.0,1.0,0.0624000138625,NCT01597505-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,61.4 (55.9 to 66.8)  ,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,antibiotic,"CB-183,315",290,175,500.0,5000.0,0.455437437134,0.997211988086,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,24,13,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,4.0,20.0,"CB-183,315",therapeutic,16,13,50.0,250.0,1.0,0.0624000138625,NCT01598311-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,59.0 (53.4 to 64.5),,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,antibiotic,"CB-183,315",285,180,500.0,5000.0,0.999995972405,0.152619871147,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,11,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,33,25,20.0,100.0,0.999840012008,0.40038253395,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",61,44,250.0,2500.0,0.999410530755,0.271120163143,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,11,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,33,25,20.0,100.0,0.999840012008,0.40038253395,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",58,48,500.0,5000.0,1.0,0.013104683434,intervention.Specific,comparator.Specific,inconclusive,inferior,0
22802252,2012,sustained,16,11,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,33,25,20.0,100.0,0.999840012008,0.40038253395,NCT01597505-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,61.4 (55.9 to 66.8)  ,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,antibiotic,"CB-183,315",290,175,500.0,5000.0,0.455437437134,0.997211988086,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,11,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,33,25,20.0,100.0,0.999840012008,0.40038253395,NCT01598311-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,59.0 (53.4 to 64.5),,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,antibiotic,"CB-183,315",285,180,500.0,5000.0,0.999995972405,0.152619871147,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,11,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.183936001327,0.999999999995,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",61,44,250.0,2500.0,0.999410530755,0.271120163143,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,11,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.183936001327,0.999999999995,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",58,48,500.0,5000.0,1.0,0.013104683434,intervention.Specific,comparator.Specific,inconclusive,inferior,0
22802252,2012,sustained,16,11,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.183936001327,0.999999999995,NCT01597505-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,61.4 (55.9 to 66.8)  ,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,antibiotic,"CB-183,315",290,175,500.0,5000.0,0.455437437134,0.997211988086,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,11,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,32,16,4.0,20.0,0.183936001327,0.999999999995,NCT01598311-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,59.0 (53.4 to 64.5),,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,antibiotic,"CB-183,315",285,180,500.0,5000.0,0.999995972405,0.152619871147,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,11,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,16,13,50.0,250.0,0.999840037596,0.263434612261,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",61,44,250.0,2500.0,0.999410530755,0.271120163143,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,11,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,16,13,50.0,250.0,0.999840037596,0.263434612261,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,"CB-183,315",58,48,500.0,5000.0,1.0,0.013104683434,intervention.Specific,comparator.Specific,inconclusive,inferior,0
22802252,2012,sustained,16,11,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,16,13,50.0,250.0,0.999840037596,0.263434612261,NCT01597505-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,61.4 (55.9 to 66.8)  ,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,antibiotic,"CB-183,315",290,175,500.0,5000.0,0.455437437134,0.997211988086,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
22802252,2012,sustained,16,11,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,50.0,250.0,"CB-183,315",therapeutic,16,13,50.0,250.0,0.999840037596,0.263434612261,NCT01598311-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,59.0 (53.4 to 64.5),,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,antibiotic,"CB-183,315",285,180,500.0,5000.0,0.999995972405,0.152619871147,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25993059,2015,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,surotomycin,,,20.0,,spores,0.5,2.5,vancomycin,therapeutic,8,8,0.5,2.5,0.999920009199,0.999920009199,NCT01085591-1,acute,250.0,2500.0,125,mg,BID,10.0,,antibiotic,surotomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,61,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,antibiotic,vancomycin,66,59,500.0,5000.0,0.29413098603,0.999340649771,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25993059,2015,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,surotomycin,,,20.0,,spores,0.5,2.5,vancomycin,therapeutic,8,8,0.5,2.5,0.999920009199,0.999920009199,NCT01085591-3,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,surotomycin,yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,58,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,antibiotic,vancomycin,66,59,500.0,5000.0,0.999340656221,0.345333712741,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25993059,2015,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,surotomycin,,,20.0,,spores,0.5,2.5,vancomycin,therapeutic,8,8,0.5,2.5,0.999920009199,0.999920009199,NCT01597505-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,surotomycin,no,290,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,79.0 (73.9 to 83.2),Non-Inferiority,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,229,antibiotic,vancomycin,280,234,500.0,5000.0,0.999999995997,0.101122945492,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25993059,2015,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,surotomycin,,,20.0,,spores,0.5,2.5,vancomycin,therapeutic,8,8,0.5,2.5,0.999920009199,0.999920009199,NCT01598311-1,acute,500.0,5000.0,250,mg,BID,10.0,,antibiotic,surotomycin,no,285,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,83.4 (78.7 to 87.2),Non-Inferiority,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,237,antibiotic,vancomycin,292,239,500.0,5000.0,0.38557995153,0.997162329539,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25993059,2015,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,0.5,2.5,surotomycin,therapeutic,8,8,0.5,2.5,0.999920009199,0.999920009199,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,surotomycin,66,61,250.0,2500.0,0.999340649771,0.29413098603,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25993059,2015,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,0.5,2.5,surotomycin,therapeutic,8,8,0.5,2.5,0.999920009199,0.999920009199,NCT01085591-6,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,59,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,antibiotic,surotomycin,67,58,500.0,5000.0,0.345333712741,0.999340656221,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25993059,2015,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,0.5,2.5,surotomycin,therapeutic,8,8,0.5,2.5,0.999920009199,0.999920009199,NCT01597505-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,83.6 (78.8 to 87.4),,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,antibiotic,surotomycin,290,229,500.0,5000.0,0.101122945492,0.999999995997,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25993059,2015,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,0.5,2.5,surotomycin,therapeutic,8,8,0.5,2.5,0.999920009199,0.999920009199,NCT01598311-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,82.1 (77.2 to 85.9),,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,antibiotic,surotomycin,285,237,500.0,5000.0,0.997162329539,0.38557995153,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25993059,2015,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,surotomycin,,,20.0,,spores,0.5,2.5,vancomycin,therapeutic,8,2,0.5,2.5,0.00111389160151,1.0,NCT01085591-7,sustained,250.0,2500.0,125,mg,BID,10.0,,antibiotic,surotomycin,yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,17,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,antibiotic,vancomycin,59,38,500.0,5000.0,0.271120163143,0.999410530755,intervention.Specific,comparator.Specific,superior,inconclusive,0
25993059,2015,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,surotomycin,,,20.0,,spores,0.5,2.5,vancomycin,therapeutic,8,2,0.5,2.5,0.00111389160151,1.0,NCT01085591-10,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,surotomycin,yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,10,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,antibiotic,vancomycin,59,38,500.0,5000.0,0.013104683434,1.0,intervention.Specific,comparator.Specific,superior,superior,1
25993059,2015,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,surotomycin,,,20.0,,spores,0.5,2.5,vancomycin,therapeutic,8,2,0.5,2.5,0.00111389160151,1.0,NCT01597505-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,surotomycin,no,290,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,60.6 (55.0 to 66.0),not superior,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,175,antibiotic,vancomycin,280,171,500.0,5000.0,0.997211988086,0.455437437134,intervention.Specific,comparator.Specific,superior,inconclusive,0
25993059,2015,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,surotomycin,,,20.0,,spores,0.5,2.5,vancomycin,therapeutic,8,2,0.5,2.5,0.00111389160151,1.0,NCT01598311-3,sustained,500.0,5000.0,250,mg,BID,10.0,,antibiotic,surotomycin,no,285,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,63.3 (57.7 to 68.7),not superior,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,180,antibiotic,vancomycin,292,172,500.0,5000.0,0.152619871147,0.999995972405,intervention.Specific,comparator.Specific,superior,inconclusive,0
25993059,2015,sustained,8,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,0.5,2.5,surotomycin,therapeutic,8,8,0.5,2.5,1.0,0.00111389160151,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,surotomycin,61,44,250.0,2500.0,0.999410530755,0.271120163143,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25993059,2015,sustained,8,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,0.5,2.5,surotomycin,therapeutic,8,8,0.5,2.5,1.0,0.00111389160151,NCT01085591-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,21,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,antibiotic,surotomycin,58,48,500.0,5000.0,1.0,0.013104683434,intervention.Specific,comparator.Specific,inferior,inferior,1
25993059,2015,sustained,8,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,0.5,2.5,surotomycin,therapeutic,8,8,0.5,2.5,1.0,0.00111389160151,NCT01597505-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,61.4 (55.9 to 66.8)  ,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,antibiotic,surotomycin,290,175,500.0,5000.0,0.455437437134,0.997211988086,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25993059,2015,sustained,8,2,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,ATCC 43596,vancomycin,,,20.0,,spores,0.5,2.5,surotomycin,therapeutic,8,8,0.5,2.5,1.0,0.00111389160151,NCT01598311-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,59.0 (53.4 to 64.5),,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,antibiotic,surotomycin,285,180,500.0,5000.0,0.999995972405,0.152619871147,intervention.Specific,comparator.Specific,inferior,inconclusive,0
16966409,2006,sustained,15,4,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,MDX1388,,75.0,140000.0,CFU,spores,20.0,80.0,CDA1 + MDX1388,therapeutic,22,15,80.0,320.0,1.0,0.00815398717102,NCT01513239-1,sustained,10.0,10.0,10,mg/kg,QD,1.0,,antibody,MDX1388,no,390,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,14.9,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,332,antibody,CDA1 + MDX1388,395,333,20.0,20.0,0.412987795232,0.996122890758,intervention.Variation,comparator.Variation,inferior,inconclusive,0
16966409,2006,sustained,15,4,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,MDX1388,,75.0,140000.0,CFU,spores,20.0,80.0,CDA1 + MDX1388,therapeutic,22,15,80.0,320.0,1.0,0.00815398717102,NCT01241552-6,sustained,10.0,10.0,10,mg/kg,QD,1.0,,antibody,MDX1388,no,386,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,17.4,superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,319,antibody,CDA1 + MDX1388,383,323,20.0,20.0,0.996192033213,0.278497343078,intervention.Variation,comparator.Variation,inferior,inconclusive,0
16966409,2006,sustained,15,4,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,MDX1388,,75.0,140000.0,CFU,spores,20.0,80.0,CDA1,therapeutic,86,28,60.0,240.0,0.999999634759,0.474426790476,NCT01241552-6,sustained,10.0,10.0,10,mg/kg,QD,1.0,,antibody,MDX1388,no,386,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,17.4,superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,319,antibody,CDA1,232,172,10.0,10.0,0.00778618091053,1.0,intervention.Variation,comparator.Variation,inconclusive,superior,0
16966409,2006,sustained,22,15,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,CDA1 + MDX1388,,75.0,140000.0,CFU,spores,80.0,320.0,MDX1388,therapeutic,15,4,20.0,80.0,0.00815398717102,1.0,NCT01513239-3,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,CDA1 + MDX1388,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.7,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,antibody,MDX1388,390,332,10.0,10.0,0.996122890758,0.412987795232,intervention.Variation,comparator.Variation,superior,inconclusive,0
16966409,2006,sustained,22,15,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,CDA1 + MDX1388,,75.0,140000.0,CFU,spores,80.0,320.0,MDX1388,therapeutic,15,4,20.0,80.0,0.00815398717102,1.0,NCT01241552-7,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,CDA1 + MDX1388,no,383,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.9,not superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,323,antibody,MDX1388,386,319,10.0,10.0,0.278497343078,0.996192033213,intervention.Variation,comparator.Variation,superior,inconclusive,0
16966409,2006,sustained,22,15,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,CDA1 + MDX1388,,75.0,140000.0,CFU,spores,80.0,320.0,CDA1,therapeutic,86,28,60.0,240.0,0.00387102291997,1.0,NCT01241552-7,sustained,20.0,20.0,10 and 10,mg/kg,QD,1.0,,antibody,CDA1 + MDX1388,no,383,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,15.9,not superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,323,antibody,CDA1,232,172,10.0,10.0,0.00130574804311,1.0,intervention.Variation,comparator.Variation,superior,superior,1
16966409,2006,sustained,86,28,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,CDA1,,75.0,140000.0,CFU,spores,60.0,240.0,MDX1388,therapeutic,15,4,20.0,80.0,0.474426790476,0.999999634759,NCT01241552-1,sustained,10.0,10.0,10,mg/kg,QD,1.0,,antibody,CDA1,no,232,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,25.9,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,172,antibody,MDX1388,386,319,10.0,10.0,1.0,0.00778618091053,intervention.Variation,comparator.Variation,inconclusive,inferior,0
16966409,2006,sustained,86,28,positive,,Golden Syrian,,hamster,clindamycin+challenge+vancomycin,cumulative mortality,therapeutic,87.0,VPI 10463,CDA1,,75.0,140000.0,CFU,spores,60.0,240.0,CDA1 + MDX1388,therapeutic,22,15,80.0,320.0,1.0,0.00387102291997,NCT01241552-1,sustained,10.0,10.0,10,mg/kg,QD,1.0,,antibody,CDA1,no,232,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,25.9,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,172,antibody,CDA1 + MDX1388,383,323,20.0,20.0,1.0,0.00130574804311,intervention.Variation,comparator.Variation,inferior,inferior,1
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,SMT19969,therapeutic,10,10,25.0,125.0,1.0,0.000436404918425,NCT02784002-1,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,6,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,antibiotic,SMT19969,14,7,400.0,4000.0,0.999870025996,0.471129153635,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,3,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,2.0,10.0,SMT19969,therapeutic,10,8,50.0,250.0,1.0,0.020694732666,NCT02784002-1,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,6,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,antibiotic,SMT19969,14,7,400.0,4000.0,0.999870025996,0.471129153635,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,SMT19969,therapeutic,10,10,25.0,125.0,1.0,9.53674316308e-07,NCT02784002-1,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,6,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,antibiotic,SMT19969,14,7,400.0,4000.0,0.999870025996,0.471129153635,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,20.0,100.0,SMT19969,therapeutic,10,8,50.0,250.0,1.0,0.000105857849119,NCT02784002-1,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,6,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,antibiotic,SMT19969,14,7,400.0,4000.0,0.999870025996,0.471129153635,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,SMT19969,therapeutic,10,10,25.0,125.0,1.0,0.00175827775963,NCT02784002-1,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,6,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,antibiotic,SMT19969,14,7,400.0,4000.0,0.999870025996,0.471129153635,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,4,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,5.0,25.0,SMT19969,therapeutic,10,8,50.0,250.0,1.0,0.0474390013112,NCT02784002-1,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,6,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,antibiotic,SMT19969,14,7,400.0,4000.0,0.999870025996,0.471129153635,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,SMT19969,therapeutic,10,10,25.0,125.0,1.0,9.53674316308e-07,NCT02784002-1,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,6,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,antibiotic,SMT19969,14,7,400.0,4000.0,0.999870025996,0.471129153635,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,fidaxomicin,,,225.0,,spores,50.0,250.0,SMT19969,therapeutic,10,8,50.0,250.0,1.0,0.000105857849119,NCT02784002-1,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,6,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,antibiotic,SMT19969,14,7,400.0,4000.0,0.999870025996,0.471129153635,intervention.Specific,comparator.Specific,inferior,inconclusive,0
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,SMT19969,therapeutic,10,9,25.0,125.0,0.999900014499,0.999900014499,NCT02784002-1,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,6,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,antibiotic,SMT19969,14,7,400.0,4000.0,0.999870025996,0.471129153635,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,2.0,10.0,SMT19969,therapeutic,10,10,50.0,250.0,0.999999995501,0.261042896769,NCT02784002-1,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,6,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,antibiotic,SMT19969,14,7,400.0,4000.0,0.999870025996,0.471129153635,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,5.0,25.0,SMT19969,therapeutic,10,9,25.0,125.0,0.999900014499,0.999900014499,NCT02784002-1,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,6,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,antibiotic,SMT19969,14,7,400.0,4000.0,0.999870025996,0.471129153635,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,fidaxomicin,,,225.0,,spores,5.0,25.0,SMT19969,therapeutic,10,10,50.0,250.0,0.999999995501,0.261042896769,NCT02784002-1,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,6,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,antibiotic,SMT19969,14,7,400.0,4000.0,0.999870025996,0.471129153635,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,SMT19969,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT02092935-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,23,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,antibiotic,SMT19969,36,28,400.0,4000.0,0.999670171555,0.281871643626,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,SMT19969,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT02092935-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,23,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,antibiotic,SMT19969,36,28,400.0,4000.0,0.999670171555,0.281871643626,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,SMT19969,therapeutic,10,10,25.0,125.0,0.999900014499,0.999900014499,NCT02092935-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,23,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,antibiotic,SMT19969,36,28,400.0,4000.0,0.999670171555,0.281871643626,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,SMT19969,therapeutic,10,10,50.0,250.0,0.999900014499,0.999900014499,NCT02092935-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,23,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,antibiotic,SMT19969,36,28,400.0,4000.0,0.999670171555,0.281871643626,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,SMT19969,therapeutic,10,10,25.0,125.0,1.0,9.53674316308e-07,NCT02092935-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,14,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,antibiotic,SMT19969,28,24,400.0,4000.0,1.0,0.0252878638239,intervention.Specific,comparator.Specific,inferior,inferior,1
25652749,2015,sustained,10,0,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,vancomycin,,,225.0,,spores,20.0,100.0,SMT19969,therapeutic,10,8,50.0,250.0,1.0,0.000105857849119,NCT02092935-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,14,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,antibiotic,SMT19969,28,24,400.0,4000.0,1.0,0.0252878638239,intervention.Specific,comparator.Specific,inferior,inferior,1
25652749,2015,sustained,10,1,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,SMT19969,therapeutic,10,9,25.0,125.0,1.0,0.000201225280758,NCT02092935-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,14,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,antibiotic,SMT19969,28,24,400.0,4000.0,1.0,0.0252878638239,intervention.Specific,comparator.Specific,inferior,inferior,1
25652749,2015,sustained,10,1,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,vancomycin,,,225.0,,spores,20.0,100.0,SMT19969,therapeutic,10,10,50.0,250.0,1.0,2.00271606436e-05,NCT02092935-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,14,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,antibiotic,SMT19969,28,24,400.0,4000.0,1.0,0.0252878638239,intervention.Specific,comparator.Specific,inferior,inferior,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,SMT19969,,,225.0,,spores,25.0,125.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02092935-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,36,therapeutic,Clinical response at test of cure,positive,participants,28,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,28,antibiotic,vancomycin,33,23,500.0,5000.0,0.281871643626,0.999670171555,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,SMT19969,,,225.0,,spores,50.0,250.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02092935-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,36,therapeutic,Clinical response at test of cure,positive,participants,28,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,28,antibiotic,vancomycin,33,23,500.0,5000.0,0.281871643626,0.999670171555,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,SMT19969,,,225.0,,spores,25.0,125.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02092935-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,36,therapeutic,Clinical response at test of cure,positive,participants,28,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,28,antibiotic,vancomycin,33,23,500.0,5000.0,0.281871643626,0.999670171555,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,acute,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,SMT19969,,,225.0,,spores,50.0,250.0,vancomycin,therapeutic,10,10,20.0,100.0,0.999900014499,0.999900014499,NCT02092935-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,36,therapeutic,Clinical response at test of cure,positive,participants,28,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,28,antibiotic,vancomycin,33,23,500.0,5000.0,0.281871643626,0.999670171555,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,SMT19969,,,225.0,,spores,25.0,125.0,fidaxomicin,therapeutic,10,3,2.0,10.0,0.000436404918425,1.0,NCT02784002-2,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,7,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,antibiotic,fidaxomicin,13,6,400.0,4000.0,0.471129153635,0.999870025996,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,SMT19969,,,225.0,,spores,25.0,125.0,fidaxomicin,therapeutic,10,0,20.0,100.0,9.53674316308e-07,1.0,NCT02784002-2,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,7,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,antibiotic,fidaxomicin,13,6,400.0,4000.0,0.471129153635,0.999870025996,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,SMT19969,,,225.0,,spores,25.0,125.0,fidaxomicin,therapeutic,10,4,5.0,25.0,0.00175827775963,1.0,NCT02784002-2,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,7,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,antibiotic,fidaxomicin,13,6,400.0,4000.0,0.471129153635,0.999870025996,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,SMT19969,,,225.0,,spores,25.0,125.0,fidaxomicin,therapeutic,10,0,50.0,250.0,9.53674316308e-07,1.0,NCT02784002-2,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,7,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,antibiotic,fidaxomicin,13,6,400.0,4000.0,0.471129153635,0.999870025996,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,8,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,SMT19969,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,3,2.0,10.0,0.020694732666,1.0,NCT02784002-2,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,7,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,antibiotic,fidaxomicin,13,6,400.0,4000.0,0.471129153635,0.999870025996,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,8,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,SMT19969,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,0,20.0,100.0,0.000105857849119,1.0,NCT02784002-2,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,7,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,antibiotic,fidaxomicin,13,6,400.0,4000.0,0.471129153635,0.999870025996,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,8,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,SMT19969,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,4,5.0,25.0,0.0474390013112,1.0,NCT02784002-2,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,7,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,antibiotic,fidaxomicin,13,6,400.0,4000.0,0.471129153635,0.999870025996,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,8,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,SMT19969,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,0,50.0,250.0,0.000105857849119,1.0,NCT02784002-2,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,7,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,antibiotic,fidaxomicin,13,6,400.0,4000.0,0.471129153635,0.999870025996,intervention.Specific,comparator.Specific,superior,inconclusive,0
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,SMT19969,,,225.0,,spores,25.0,125.0,fidaxomicin,therapeutic,10,9,2.0,10.0,0.999900014499,0.999900014499,NCT02784002-2,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,7,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,antibiotic,fidaxomicin,13,6,400.0,4000.0,0.471129153635,0.999870025996,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,SMT19969,,,225.0,,spores,25.0,125.0,fidaxomicin,therapeutic,10,9,5.0,25.0,0.999900014499,0.999900014499,NCT02784002-2,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,7,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,antibiotic,fidaxomicin,13,6,400.0,4000.0,0.471129153635,0.999870025996,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,SMT19969,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,9,2.0,10.0,0.261042896769,0.999999995501,NCT02784002-2,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,7,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,antibiotic,fidaxomicin,13,6,400.0,4000.0,0.471129153635,0.999870025996,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,SMT19969,,,225.0,,spores,50.0,250.0,fidaxomicin,therapeutic,10,9,5.0,25.0,0.261042896769,0.999999995501,NCT02784002-2,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,7,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,antibiotic,fidaxomicin,13,6,400.0,4000.0,0.471129153635,0.999870025996,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
25652749,2015,sustained,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,SMT19969,,,225.0,,spores,25.0,125.0,vancomycin,therapeutic,10,0,20.0,100.0,9.53674316308e-07,1.0,NCT02092935-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,28,therapeutic,Sustained clinical response,positive,participants,24,superior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,24,antibiotic,vancomycin,23,14,500.0,5000.0,0.0252878638239,1.0,intervention.Specific,comparator.Specific,superior,superior,1
25652749,2015,sustained,10,8,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,12.0,630,SMT19969,,,225.0,,spores,50.0,250.0,vancomycin,therapeutic,10,0,20.0,100.0,0.000105857849119,1.0,NCT02092935-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,28,therapeutic,Sustained clinical response,positive,participants,24,superior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,24,antibiotic,vancomycin,23,14,500.0,5000.0,0.0252878638239,1.0,intervention.Specific,comparator.Specific,superior,superior,1
25652749,2015,sustained,10,9,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,SMT19969,,,225.0,,spores,25.0,125.0,vancomycin,therapeutic,10,1,20.0,100.0,0.000201225280758,1.0,NCT02092935-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,28,therapeutic,Sustained clinical response,positive,participants,24,superior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,24,antibiotic,vancomycin,23,14,500.0,5000.0,0.0252878638239,1.0,intervention.Specific,comparator.Specific,superior,superior,1
25652749,2015,sustained,10,10,positive,SPF,Golden Syrian,,hamster,clindamycin+challenge,cumulative mortality,therapeutic,27.0,BI1,SMT19969,,,225.0,,spores,50.0,250.0,vancomycin,therapeutic,10,1,20.0,100.0,2.00271606436e-05,1.0,NCT02092935-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,SMT19969,no,28,therapeutic,Sustained clinical response,positive,participants,24,superior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,24,antibiotic,vancomycin,23,14,500.0,5000.0,0.0252878638239,1.0,intervention.Specific,comparator.Specific,superior,superior,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,0.2,1.0,0.999920009199,0.999920009199,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,0.2,1.0,0.999920009199,0.999920009199,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,0.2,1.0,0.999920009199,0.999920009199,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,0.2,1.0,0.999920009199,0.999920009199,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,Tiacumicins B,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,0.2,1.0,0.999920009199,0.999920009199,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,Tiacumicins B,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,0.2,1.0,0.999920009199,0.999920009199,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,Tiacumicins B,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,Tiacumicins B,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,Tiacumicins B,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,Tiacumicins B,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,3,1.0,5.0,0.9999500035,0.9999500035,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,3,1.0,5.0,0.9999500035,0.9999500035,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,3,1.0,5.0,0.9999500035,0.9999500035,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,3,1.0,5.0,0.9999500035,0.9999500035,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,Tiacumicins B,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,3,1.0,5.0,0.9999500035,0.9999500035,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,Tiacumicins B,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,3,1.0,5.0,0.9999500035,0.9999500035,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,Tiacumicins B,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,Tiacumicins B,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,Tiacumicins B,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,Tiacumicins B,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,Tiacumicins B,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,Tiacumicins B,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,Tiacumicins B,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,Tiacumicins B,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02179658-1,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,87,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,antibiotic,vancomycin,108,95,500.0,5000.0,0.998961657439,0.27235018616,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02743234-3,acute,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,8,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,antibiotic,vancomycin,16,3,500.0,5000.0,0.191476570981,0.999999972408,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02218372-1,acute,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,77.6 (68.0 to 85.4),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,antibiotic,vancomycin,44,31,500.0,5000.0,0.247703825407,0.999999525213,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT01818141-1,acute,400.0,4000.0,200,mg,BID,10.0,200 mg BID for 10 days,antibiotic,Tiacumicins B,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,11,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,antibiotic,vancomycin,9,6,500.0,5000.0,0.102257630121,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT01818141-3,acute,400.0,4000.0,200,mg,BID,10.0,200mg BID for 10 days,antibiotic,Tiacumicins B,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,4,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,antibiotic,vancomycin,5,5,500.0,5000.0,1.0,0.0719937217368,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02254967-1,acute,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,138,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,antibiotic,vancomycin,179,147,500.0,5000.0,0.998234719388,0.267028850166,intervention.Variation,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,Tiacumicins B,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,Tiacumicins B,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,Tiacumicins B,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,Tiacumicins B,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,Tiacumicins B,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,Tiacumicins B,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,Tiacumicins B,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,Tiacumicins B,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,Tiacumicins B,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,Tiacumicins B,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,Tiacumicins B,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,Tiacumicins B,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,Tiacumicins B,15,12,200.0,2000.0,0.999860030095,0.36119511036,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-1,acute,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,10,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,antibiotic,Tiacumicins B,16,15,400.0,4000.0,1.0,0.0676904841494,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,14,10,100.0,1000.0,0.36119511036,0.999860030095,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-3,acute,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,12,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,16,15,400.0,4000.0,0.999999989503,0.156275007238,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,Tiacumicins B,14,10,100.0,1000.0,0.0676904841494,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-5,acute,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,15,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,antibiotic,Tiacumicins B,15,12,200.0,2000.0,0.156275007238,0.999999989503,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,0.999920009199,0.999920009199,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,Tiacumicins B,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,0.999920009199,0.999920009199,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,Tiacumicins B,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,0.999920009199,0.999920009199,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,Tiacumicins B,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,0.999920009199,0.999920009199,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,Tiacumicins B,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,0.999920009199,0.999920009199,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,Tiacumicins B,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,0.999920009199,0.999920009199,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,Tiacumicins B,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,Tiacumicins B,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,Tiacumicins B,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,Tiacumicins B,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,Tiacumicins B,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,Tiacumicins B,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,Tiacumicins B,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,Tiacumicins B,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,Tiacumicins B,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,Tiacumicins B,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,Tiacumicins B,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,Tiacumicins B,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,Tiacumicins B,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,3,1.0,5.0,0.9999500035,0.9999500035,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,Tiacumicins B,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,3,1.0,5.0,0.9999500035,0.9999500035,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,Tiacumicins B,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,3,1.0,5.0,0.9999500035,0.9999500035,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,Tiacumicins B,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,3,1.0,5.0,0.9999500035,0.9999500035,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,Tiacumicins B,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,3,1.0,5.0,0.9999500035,0.9999500035,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,Tiacumicins B,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,3,1.0,5.0,0.9999500035,0.9999500035,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,Tiacumicins B,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,Tiacumicins B,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,Tiacumicins B,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,Tiacumicins B,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,Tiacumicins B,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,Tiacumicins B,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,Tiacumicins B,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,Tiacumicins B,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,Tiacumicins B,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,Tiacumicins B,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,Tiacumicins B,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,Tiacumicins B,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,Tiacumicins B,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,Tiacumicins B,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,Tiacumicins B,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,Tiacumicins B,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,Tiacumicins B,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,Tiacumicins B,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,Tiacumicins B,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
1929250,1991,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,Tiacumicins B,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,Tiacumicins B,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,Tiacumicins B,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,Tiacumicins B,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,Tiacumicins B,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,Tiacumicins B,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02179658-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,95,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,antibiotic,Tiacumicins B,104,87,400.0,4000.0,0.27235018616,0.998961657439,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02743234-5,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,3,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,antibiotic,Tiacumicins B,24,8,400.0,4000.0,0.999999972408,0.191476570981,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02218372-2,acute,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,70.5 (54.6 to 83.2),,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,antibiotic,Tiacumicins B,98,76,400.0,4000.0,0.999999525213,0.247703825407,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT01818141-2,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,6,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,antibiotic,Tiacumicins B,12,11,400.0,4000.0,1.0,0.102257630121,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT01818141-4,acute,500.0,5000.0,125,mg,QID,10.0,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,5,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,antibiotic,Tiacumicins B,7,4,400.0,4000.0,0.0719937217368,1.0,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,acute,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT02254967-2,acute,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,147,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,antibiotic,Tiacumicins B,177,138,400.0,5600.0,0.267028850166,0.998234719388,intervention.Specific,comparator.Variation,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,0,0.2,1.0,1.52587890617e-05,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,0,0.2,1.0,1.52587890617e-05,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,0,0.2,1.0,1.52587890617e-05,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,0,0.2,1.0,1.52587890617e-05,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,1,1.0,5.0,0.000259399414058,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,1,1.0,5.0,0.000259399414058,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,1,1.0,5.0,0.000259399414058,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,1,1.0,5.0,0.000259399414058,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,3,5.0,25.0,0.0040276633743,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,3,5.0,25.0,0.0040276633743,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,3,5.0,25.0,0.0040276633743,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,vancomycin,therapeutic,8,3,5.0,25.0,0.0040276633743,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
1929250,1991,sustained,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,0,1.0,5.0,0.0309240451535,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,0,1.0,5.0,0.0309240451535,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,0,1.0,5.0,0.0309240451535,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
1929250,1991,sustained,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,0,1.0,5.0,0.0309240451535,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
1929250,1991,sustained,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
1929250,1991,sustained,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inconclusive,superior,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,0,0.2,1.0,1.52587890617e-05,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,0,0.2,1.0,1.52587890617e-05,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,0,0.2,1.0,1.52587890617e-05,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,0,0.2,1.0,1.52587890617e-05,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,1,1.0,5.0,0.000259399414058,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,1,1.0,5.0,0.000259399414058,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,1,1.0,5.0,0.000259399414058,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,1,1.0,5.0,0.000259399414058,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,3,5.0,25.0,0.0040276633743,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,3,5.0,25.0,0.0040276633743,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,3,5.0,25.0,0.0040276633743,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,vancomycin,therapeutic,8,3,5.0,25.0,0.0040276633743,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,5,0,1.0,5.0,0.00097656249999,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,5,0,1.0,5.0,0.00097656249999,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,5,0,1.0,5.0,0.00097656249999,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,5,0,1.0,5.0,0.00097656249999,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,inconclusive,superior,0
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,inconclusive,superior,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,0,0.2,1.0,1.52587890617e-05,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,0,0.2,1.0,1.52587890617e-05,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,0,0.2,1.0,1.52587890617e-05,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,0,0.2,1.0,1.52587890617e-05,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,1,1.0,5.0,0.000259399414058,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,1,1.0,5.0,0.000259399414058,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,1,1.0,5.0,0.000259399414058,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,1,1.0,5.0,0.000259399414058,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,3,5.0,25.0,0.0040276633743,1.0,NCT02179658-3,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,70,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,antibiotic,vancomycin,108,71,500.0,5000.0,0.440092069859,0.998961656862,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,3,5.0,25.0,0.0040276633743,1.0,NCT02743234-9,sustained,400.0,4000.0,200,mg,BID,10.0,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,antibiotic,vancomycin,16,5,500.0,5000.0,0.112261880394,0.999999999998,intervention.Specific,comparator.Specific,superior,inconclusive,0
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,3,5.0,25.0,0.0040276633743,1.0,NCT02218372-3,sustained,400.0,4000.0,200,mg,BID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,94.7 (87.1 to 98.5),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,antibiotic,vancomycin,31,23,500.0,5000.0,0.00485411467257,1.0,intervention.Specific,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,5.0,25.0,vancomycin,therapeutic,8,3,5.0,25.0,0.0040276633743,1.0,NCT02254967-3,sustained,400.0,5600.0,200,mg,BID,5.0,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,124,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,antibiotic,vancomycin,179,106,500.0,5000.0,0.0179080103424,1.0,intervention.Variation,comparator.Specific,superior,superior,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,Tiacumicins B,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,Tiacumicins B,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,Tiacumicins B,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,0.999920009199,0.999920009199,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,Tiacumicins B,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,Tiacumicins B,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,Tiacumicins B,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,Tiacumicins B,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,Tiacumicins B,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,Tiacumicins B,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,Tiacumicins B,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,Tiacumicins B,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,5,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.0936884497584,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,Tiacumicins B,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,Tiacumicins B,12,12,200.0,2000.0,0.999999995501,0.227565158008,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-7,sustained,100.0,1000.0,50,mg,BID,10.0,50 mg,antibiotic,Tiacumicins B,yes,10,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,antibiotic,Tiacumicins B,15,14,400.0,4000.0,0.999900019497,0.441682092677,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,10,9,100.0,1000.0,0.227565158008,0.999999995501,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-9,sustained,200.0,2000.0,100,mg,BID,10.0,100 mg,antibiotic,Tiacumicins B,yes,12,therapeutic,Recurrence Rate.,positive,participants,0,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,antibiotic,Tiacumicins B,15,14,400.0,4000.0,0.292929143714,0.999999989502,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,Tiacumicins B,10,9,100.0,1000.0,0.441682092677,0.999900019497,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,8,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,Tiacumicins B,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,0.999920009199,0.999920009199,NCT00097422-11,sustained,400.0,4000.0,200,mg,BID,10.0,200 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Recurrence Rate.,positive,participants,1,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,antibiotic,Tiacumicins B,12,12,200.0,2000.0,0.999999989502,0.292929143714,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,8,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,1.0,1.52587890617e-05,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,Tiacumicins B,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,1.0,1.52587890617e-05,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,Tiacumicins B,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,1.0,1.52587890617e-05,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,Tiacumicins B,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
1929250,1991,sustained,8,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,1.0,1.52587890617e-05,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,Tiacumicins B,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
1929250,1991,sustained,8,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,1.0,1.52587890617e-05,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,Tiacumicins B,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,1.0,1.52587890617e-05,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,Tiacumicins B,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,1.0,1.52587890617e-05,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,Tiacumicins B,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
1929250,1991,sustained,8,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,1.0,1.52587890617e-05,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,Tiacumicins B,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
1929250,1991,sustained,8,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,1.0,1.52587890617e-05,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,Tiacumicins B,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,1.0,1.52587890617e-05,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,Tiacumicins B,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,1.0,1.52587890617e-05,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,Tiacumicins B,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
1929250,1991,sustained,8,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,0.2,1.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,1.0,1.52587890617e-05,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,Tiacumicins B,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
1929250,1991,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,3,1.0,5.0,1.0,0.0309240451535,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,Tiacumicins B,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,3,1.0,5.0,1.0,0.0309240451535,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,Tiacumicins B,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,3,1.0,5.0,1.0,0.0309240451535,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,Tiacumicins B,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
1929250,1991,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,3,1.0,5.0,1.0,0.0309240451535,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,Tiacumicins B,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
1929250,1991,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.00097656249999,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,Tiacumicins B,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.00097656249999,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,Tiacumicins B,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.00097656249999,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,Tiacumicins B,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
1929250,1991,sustained,5,0,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,1.0,0.00097656249999,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,Tiacumicins B,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
1929250,1991,sustained,8,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,1.0,0.000259399414058,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,Tiacumicins B,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,1.0,0.000259399414058,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,Tiacumicins B,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,1.0,0.000259399414058,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,Tiacumicins B,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
1929250,1991,sustained,8,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,1.0,0.000259399414058,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,Tiacumicins B,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
1929250,1991,sustained,8,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,1.0,0.000259399414058,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,Tiacumicins B,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,1.0,0.000259399414058,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,Tiacumicins B,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,1.0,0.000259399414058,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,Tiacumicins B,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
1929250,1991,sustained,8,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,1.0,0.000259399414058,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,Tiacumicins B,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
1929250,1991,sustained,8,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,1.0,0.000259399414058,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,Tiacumicins B,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,1.0,0.000259399414058,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,Tiacumicins B,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,1.0,0.000259399414058,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,Tiacumicins B,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
1929250,1991,sustained,8,1,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,1.0,5.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,1.0,0.000259399414058,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,Tiacumicins B,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,5,3,1.0,5.0,0.0936884497584,1.0,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,Tiacumicins B,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,5,3,1.0,5.0,0.0936884497584,1.0,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,Tiacumicins B,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,5,3,1.0,5.0,0.0936884497584,1.0,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,Tiacumicins B,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inconclusive,inferior,0
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,5,3,1.0,5.0,0.0936884497584,1.0,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,Tiacumicins B,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inconclusive,inferior,0
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,Tiacumicins B,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,Tiacumicins B,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inconclusive,inconclusive,1
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,Tiacumicins B,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inconclusive,inferior,0
1929250,1991,sustained,5,5,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,,2926,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,5,5,5.0,25.0,0.9999500035,0.9999500035,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,Tiacumicins B,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inconclusive,inferior,0
1929250,1991,sustained,8,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,1.0,0.0040276633743,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,Tiacumicins B,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,1.0,0.0040276633743,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,Tiacumicins B,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,1.0,0.0040276633743,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,Tiacumicins B,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
1929250,1991,sustained,8,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,0.2,1.0,1.0,0.0040276633743,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,Tiacumicins B,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
1929250,1991,sustained,8,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,1.0,0.0040276633743,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,Tiacumicins B,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,1.0,0.0040276633743,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,Tiacumicins B,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,1.0,0.0040276633743,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,Tiacumicins B,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
1929250,1991,sustained,8,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,1.0,5.0,1.0,0.0040276633743,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,Tiacumicins B,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
1929250,1991,sustained,8,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,1.0,0.0040276633743,NCT02179658-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,71,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,antibiotic,Tiacumicins B,104,70,400.0,4000.0,0.998961656862,0.440092069859,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,1.0,0.0040276633743,NCT02743234-11,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,11,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,antibiotic,Tiacumicins B,24,13,400.0,4000.0,0.999999999998,0.112261880394,intervention.Specific,comparator.Specific,inferior,inconclusive,0
1929250,1991,sustained,8,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,1.0,0.0040276633743,NCT02218372-4,sustained,500.0,5000.0,125,mg,QID,10.0,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,77.4 (58.9 to 90.4),,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,antibiotic,Tiacumicins B,76,71,400.0,4000.0,1.0,0.00485411467257,intervention.Specific,comparator.Specific,inferior,inferior,1
1929250,1991,sustained,8,3,positive,,Golden Syrian,M,hamster,clindamycin+challenge,cumulative mortality,therapeutic,1.0,ATCC9689,vancomycin,,90.0,1000000.0,,,5.0,25.0,Tiacumicins B,therapeutic,8,8,5.0,25.0,1.0,0.0040276633743,NCT02254967-4,sustained,500.0,5000.0,125,mg,QID,10.0,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,106,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,antibiotic,Tiacumicins B,177,124,400.0,5600.0,1.0,0.0179080103424,intervention.Specific,comparator.Variation,inferior,inferior,1
